Skip to main content
eLife logoLink to eLife
. 2021 May 4;10:e60467. doi: 10.7554/eLife.60467

Qki regulates myelinogenesis through Srebp2-dependent cholesterol biosynthesis

Xin Zhou 1,2,, Seula Shin 1,3,, Chenxi He 4,, Qiang Zhang 1, Matthew N Rasband 5, Jiangong Ren 1, Congxin Dai 1,6, Rocío I Zorrilla-Veloz 1,3, Takashi Shingu 1, Liang Yuan 1,7, Yunfei Wang 8, Yiwen Chen 9, Fei Lan 4, Jian Hu 1,3,10,
Editors: Marianne E Bronner11, Jian Xu12
PMCID: PMC8139834  PMID: 33942715

Abstract

Myelination depends on timely, precise control of oligodendrocyte differentiation and myelinogenesis. Cholesterol is the most abundant component of myelin and essential for myelin membrane assembly in the central nervous system. However, the underlying mechanisms of precise control of cholesterol biosynthesis in oligodendrocytes remain elusive. In the present study, we found that Qki depletion in neural stem cells or oligodendrocyte precursor cells in neonatal mice resulted in impaired cholesterol biosynthesis and defective myelinogenesis without compromising their differentiation into Aspa+Gstpi+ myelinating oligodendrocytes. Mechanistically, Qki-5 functions as a co-activator of Srebp2 to control transcription of the genes involved in cholesterol biosynthesis in oligodendrocytes. Consequently, Qki depletion led to substantially reduced concentration of cholesterol in mouse brain, impairing proper myelin assembly. Our study demonstrated that Qki-Srebp2-controlled cholesterol biosynthesis is indispensable for myelinogenesis and highlights a novel function of Qki as a transcriptional co-activator beyond its canonical function as an RNA-binding protein.

Research organism: Mouse

Introduction

The brain is the most cholesterol-rich organ, accounting for 23% of the total cholesterol in the body even though the brain represents only 2% of the total body weight (Dietschy and Turley, 2004). About 70–80% of the brain cholesterol resides in myelin, a compact multilayer membrane structure that is generated by oligodendrocytes in the central nervous system (CNS), and myelin is critical for rapid saltatory nerve conduction (Armati and Mathey, 2010). Myelin is a lipid-rich material, and cholesterol accounts for the highest molar percentage (~52%) among all myelin lipids (Chrast et al., 2011). Consistently, the rate of cholesterol biosynthesis in the mouse brain is highest during the first three weeks after birth (Dietschy and Turley, 2004; Quan et al., 2003), the same period in which the rate of myelinogenesis is highest (Armati and Mathey, 2010).

The brain depends extensively on de novo cholesterol biosynthesis, which is mainly carried out by oligodendrocytes and astrocytes, as the blood-brain barrier blocks the uptake of cholesterol from the circulation (Camargo et al., 2017; Saher et al., 2005). Genetic ablation of squalene synthase (Fdft1), an enzyme involved in the early step of cholesterol biosynthesis, in oligodendrocyte lineage cells has resulted in failure of proper myelination (Saher et al., 2005). The importance of cholesterol biosynthesis in myelination is also implicated in various neurological disorders accompanied by myelin defects. For example, hereditary diseases such as Smith–Lemli–Opitz syndrome (SLOS), desmosterolosis, and lathosterolosis are caused by mutations of the cholesterol biosynthesis genes encoding 7-dehydrocholesterol reductase (DHCR7), 24-dehydrocholesterol reductase (DHCR24), and sterol-C5-desaturase (SC5D), respectively (Kanungo et al., 2013; Nwokoro et al., 2001; Porter and Herman, 2011). In particular, SLOS patients present with cognitive defects and delayed motor and language development along with hypomyelination (Porter and Herman, 2011). Patients with desmosterolosis have defects in the corpus callosum, thinning of white matter, and seizures (Zerenturk et al., 2013). One of the major neurodevelopmental disorders, schizophrenia, usually develops in late adolescence or early adulthood when maturation of the brain, including steps such as myelin biogenesis, occurs (Le Hellard et al., 2010; Steen et al., 2017). White matter abnormalities often occur in schizophrenic patients in association with reduced lipid metabolism (Steen et al., 2017). Of note, among the 108 schizophrenia-associated genomic loci, one is on chromosome 22q13.2, which includes SREBF2 gene that encodes sterol regulatory element-binding protein 2 (SREBP2), the major transcription factor that regulates cholesterol biosynthesis (Horton et al., 2002; Le Hellard et al., 2010; Steen et al., 2017). Antipsychotic drugs are known to increase SREBP2 activity, resulting in upregulated expression of the genes involved in cholesterol biosynthesis (Fernø et al., 2005; Le Hellard et al., 2009), suggesting a potential role of SREBP2-mediated cholesterol biosynthesis in the pathogenesis of schizophrenia. Besides the neurological diseases accompanied by myelination defects, reduction in cholesterol biosynthesis is also associated with neurodegenerative diseases such as Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, and autism spectrum disorders, for which myelin involvement has been documented but less understood (Leoni and Caccia, 2014; Mohamed et al., 2018; Segatto et al., 2019; Tsunemi et al., 2012; Xiang et al., 2011). Taken together, cholesterol biosynthesis plays a pivotal role in brain function, particularly myelination, and dysregulated cholesterol metabolism causes various neurological diseases. Yet the underlying mechanisms of precise control of cholesterol biosynthesis in oligodendrocytes during developmental myelination remain elusive.

Mammalian Quaking (Qk) undergoes alternative splicing to express the RNA-binding proteins Qki-5, Qki-6, and Qki-7 (Darbelli and Richard, 2016). Various studies have extensively demonstrated that Qki regulates the RNA processing of the genes encoding myelin basic protein (MBP), myelin-associated glycoprotein (MAG), p27kip1, and neurofascin 155 in oligodendrocytes (Darbelli et al., 2016; Larocque et al., 2005; Larocque et al., 2002; Li et al., 2000; Zhao et al., 2010). The quaking viable (qkv) mouse is a spontaneous recessive mutant with an approximate 1-Mbp deletion in the upstream of Qk locus, leading to diminished expression of Qki in oligodendrocytes (Ebersole et al., 1996; Hardy et al., 1996). Qkv homozygotes suffer from tremor and early death due to severe hypomyelination in the CNS (Sidman et al., 1964). Previous studies showed that qkv mice exhibited reduced myelin lipid content, including cholesterol (Baumann et al., 1968; Singh et al., 1971), and this phenomenon was thought to be secondary to impaired differentiation and maturation of oligodendrocytes (Chen et al., 2007; Darbelli et al., 2016; Larocque et al., 2005). However, similar numbers of oligodendrocytes in some regions of the CNS in qkv mice and control mice and even hyperplasia in these regions in the former mice were observed (Doukhanine et al., 2010; Hardy et al., 1996; Myers et al., 2016). These contradictory data suggested that Qki might regulate myelination in the CNS through mechanisms besides controlling oligodendrocyte differentiation and that reduced myelin lipid in qkv mice could be a direct consequence of Qk loss rather than secondary to impaired oligodendrocyte differentiation. Interestingly, our recent study demonstrated that Qki is not required for mature oligodendrocyte survival in adult mice, and that Qki-5 forms a complex with peroxisome proliferator-activated receptor beta (PPARβ)-retinoid X receptor alpha (RXRα) to transcriptionally control fatty acid metabolism, which is essential for mature myelin maintenance (Zhou et al., 2020). We therefore hypothesized that Qki might transcriptionally regulate lipid metabolism, such as cholesterol biosynthesis, during developmental myelination in young mice.

In the present study, using conditional Qk-knockout mice specifically lacking expression of Qki in either neural stem cells (NSCs) or oligodendrocyte precursor cells (OPCs) during the crucial myelin-forming period of postnatal brain development, we identified a critical, previously uncharacterized phenomenon that Qki-depleted NSCs and OPCs can still differentiate into Aspa+/Gstpi+ myelinating oligodendrocytes. However, these cells do not form myelin properly due to impaired cholesterol biosynthesis. We also found that Qki-5 interacted with Srebp2 and activated its transcriptional activity for the genes involved in cholesterol biosynthesis. Deletion of Qk almost completely abolished expression of various cholesterol biosynthesis genes in oligodendrocytes and reduced the cholesterol content in the corpus callosum tissues in Qk-depleted mice. Our study highlights a novel function of Qki as a co-activator of Srebp2 in developing brain beyond its canonical function as an RNA-binding protein.

Results

Qki depletion in mouse NSCs leads to hypomyelination in the CNS

We asked whether the hypomyelination induced by knockout of Qk is due to impaired oligodendrocyte differentiation or defective myelinogenesis. Unlike the Olig2-Cre and Pdgfra-CreERT2, the Nestin-CreERT2 transgene, in which expression of tamoxifen-inducible Cre is under the control of the Nestin promoter, enabled us to investigate whether knockout of Qk affects differentiation of the entire oligodendrocyte lineage, including the step from NSCs to OPCs. We crossed mice bearing the Qk-loxP allele with mice bearing the Nestin-CreERT2 transgene, and Qk was specifically deleted in NSCs by injecting tamoxifen into C57BL/6J Nestin-CreERT2;QkL/L pups at postnatal day 7 (P7; in all subsequent experiments using this cohort)—the time point when oligodendrocyte differentiation and myelinogenesis start (Figure 1AArmati and Mathey, 2010). About 12 days after tamoxifen injection, Nestin-CreERT2;QkL/L mice (hereafter denoted as ‘Qk-Nestin-iCKO mice’) began to exhibit visible tremors and ataxia accompanied by a significant reduction in coordinate movement as measured using the rotarod test and a marked growth retardation (Figure 1B–D, Figure 1—figure supplement 1A, Video 1). Neurological deficits in Qk-Nestin-iCKO mice progressed quite rapidly, and the mice eventually displayed hunched posture, paralysis, and hyperpnea, with a median survival duration of 13 days after tamoxifen injection (Figure 1E). In contrast, Nestin-CreERT2;wild-type (WT), Nestin-CreERT2;QkL/+, and QkL/L littermates, which were also injected with tamoxifen in the same manner, were phenotypically normal. Thus, these littermates were used as control mice in subsequent experiments unless specified otherwise.

Figure 1. Deletion of Qk in mouse neural stem cells leads to hypomyelination in the central nervous system.

(A) Schema of the generation of Qk-Nestin-iCKO mice. (B) Representative images of severe hind limb paralysis in Qk-Nestin-iCKO mice 2 weeks after tamoxifen injection. Ctrl: control. (C) Latency of mice falling off the rotarod at a constant speed (5 rpm). n = 6 mice in the Qk-Nestin-iCKO group; n = 9 mice in the control group. (D) Body weights of Qk-Nestin-iCKO mice (n = 29) and control mice (n = 22) 12 days after tamoxifen injection. (E) Kaplan–Meier curves of and log-rank test results for overall survival in Qk-Nestin-iCKO mice (n = 157) and control mice (n = 153). (F) Representative images of and quantification of immunofluorescent staining of MBP, PLP, MAG, GFP, and Iba1 in the corpus callosum tissues in Qk-Nestin-iCKO mice (n = 3) and control mice (n = 4) 2 weeks after tamoxifen injection. Scale bars, 50 μm. (G) Representative images of and quantification of immunofluorescent staining of MBP and Iba1 in the optic nerves in Qk-Nestin-iCKO mice (n = 3) and control mice (n = 4) 2 weeks after tamoxifen injection. Scale bars, 50 μm. (H) Representative electron micrographs of the optic nerves in Qk-Nestin-iCKO mice and control mice with quantification of the percentage of myelinated axons and g-ratios 2 weeks after tamoxifen injection (n = 3 mice/group). Scale bars, 500 nm. (I) Representative images and quantification of immunofluorescent staining of amyloid precursor protein (App) in the corpus callosum tissues in Qk-Nestin-iCKO mice (n = 3) and control mice (n = 4) 2 weeks after tamoxifen injection. Scale bars, 50 μm. Data are shown as mean ± s.d. and were analyzed using Student's t test. ***p<0.001; ****p<0.0001; ns: not significant.

Figure 1—source data 1. Exact p-values for statistical analysis.

Figure 1.

Figure 1—figure supplement 1. Deletion of Qk in mouse neural stem cells leads to hypomyelination in the central nervous system.

Figure 1—figure supplement 1.

(A) Kaplan–Meier curves of and log-rank test results for quaking phenotype-free survival of QkL/L mice (n = 23), Nestin-CreERT2;WT mice (n = 8), Nestin-CreERT2;QkL/+ mice (n = 122), and Nestin-CreERT2;QkL/L mice (n = 157). (B) Representative electron micrographs of and quantification of the g-ratio in the optic nerves in Qk-Nestin-iCKO mice and control mice 2 weeks after tamoxifen injection (n = 3 mice/group). Scale bars, 2 μm. (C) Representative images of immunofluorescent staining of MBP in the corpus callosum tissues in Qk-Nestin-iCKO mice and control mice 5, 10, and 14 days after tamoxifen injection (n = 3 mice/group). Scale bar, 50 μm. (D) Representative images of immunofluorescent staining of Caspr, AnkG, and PanNav in the optic nerves of Qk-Nestin-iCKO mice and controls 2 weeks after tamoxifen injection (n = 3 mice/group). Scale bars, 1 μm. (E, F) Representative images of immunofluorescent staining of Caspr and AnkG in the optic nerves of Qk-Nestin-iCKO mice and control mice 7, 10, and 14 days after tamoxifen injection (n = 3 mice/group). Scale bar, (E) 5 μm, (F) 10 μm. (G, H) Quantification of total number of nodes (G) and % of nodes with both paranodes (H) in the optic nerves of Qk-Nestin-iCKO mice and control mice 7, 10, and 14 days after tamoxifen injection (n = 3 mice/group). Data are shown as mean ± s.d. and were analyzed using Student's t test. *p<0.05; ***p<0.001; ****p<0.0001. (I, J) Quantification of axonal diameter (I) and density of axon (J) in the mice in (B). Data are shown as mean ± s.d. and were analyzed using Student's t test. ns: not significant. (K–M) Representative images (K) of and quantification of axon initial segment length (L) and cumulative frequency (M) in the cortex tissues in Qk-Nestin-iCKO mice and control mice 2 weeks after tamoxifen injection (n = 3 mice/group). Scale bars, 50 μm. Data are shown as mean ± s.d. and were analyzed using Student's t test. ns: not significant.

Video 1. Defect in motor coordination displaying tremors and ataxia in Qk-Nestin-iCKO mice.

Download video file (14.6MB, mp4)

Two weeks after tamoxifen injection (in all subsequent experiments unless specified otherwise), Qk-Nestin-iCKO mice had severe hypomyelination as evidenced by substantial reduction in the levels of expression of MBP, proteolipid protein (PLP), and MAG (23.7%, 28.2%, and 16.6% of those in control mice, respectively) and a marked increase in the frequency (4.1-fold greater than that in control mice) of Iba1+ microglial infiltration in the corpus callosum tissues (Figure 1F). To further determine the effect of Qki on myelin formation, we crossed mice bearing the mTmG reporter line (Muzumdar et al., 2007) with Qk-Nestin-iCKO mice or control mice. The mTmG reporter, in which expression of cell membrane-localized tdTomato (mT) is replaced by cell membrane-localized EGFP (mG) in Cre recombinase-expressing cells, enabled us to trace newly formed myelin (after tamoxifen injection) according to the membrane-bound GFP signals. The percentage of the GFP+ area in the corpus callosum tissues in Qk-Nestin-iCKO;mTmG mice markedly decreased relative to that in control Nestin-CreERT2;mTmG mice (10.6% vs. 68.7%; Figure 1F). Similarly, hypomyelination accompanied by microglial infiltration was observed in the optic nerves in Qk-Nestin-iCKO mice (Figure 1G). In line with these findings, ultrastructural analyses of myelin sheaths in the optic nerves using transmission electron microscopy revealed that only 23.3% of the axons were myelinated in Qk-Nestin-iCKO mice, whereas compact myelin formed in 79.0% of the axons in control mice (Figure 1H, Figure 1—figure supplement 1B). The myelin sheaths wrapping the sparse axons in Qk-Nestin-iCKO mice were considerably thinner than those in control mice and failed to form the compact myelin structure (g-ratio, 0.94 vs. 0.78; p<0.0001; Figure 1H). We further performed a time-course analysis of MBP expression in the corpus callosum to compare the efficiency of myelin formation between Qk-Nestin-iCKO mice and control mice during the critical time of myelin growth (P12–P21). Qki depletion slowed down the myelin formation during P12–P21, a time frame in which myelin is initiated and actively generated, ultimately resulting in failure of proper myelin formation at P21 (Figure 1—figure supplement 1C). Notably, we observed that Qki depletion leads to defect in formation of node of Ranvier at P21 in the optic nerve, where rapid and robust myelination occurs during development, using antibodies against paranodal protein (Caspr) and nodal proteins (AnkG and PanNav) (Figure 1—figure supplement 1D). As node formation was severely affected at P21, we further examined when the defect is initiated during early myelin development. Previous studies showed that clustering of ion channels at the nodes requires proper myelination (Rasband and Peles, 2021; Rasband et al., 1999). As myelination is rapidly formed at its peak from P14 in the optic nerve (Mayoral et al., 2018), we monitored earlier times (P14 and P17) to ask if myelin defect induced by Qki depletion affects de novo formation of nodes. Defect in node formation was observed as early as P14, which cannot be overcome at P21 (Figure 1—figure supplement 1E, F), and this observation is in line with the defect in myelination observed from P12 (Figure 1—figure supplement 1C). Specifically, total number of nodes (including both intact and the incomplete nodes) in the optic nerve was decreased upon Qki depletion (Figure 1—figure supplement 1G). Importantly, the percentage of intact nodes among the total nodes was significantly reduced with Qki depletion (Figure 1—figure supplement 1H). Our observation suggests that the failure of myelin formation upon Qki depletion leads to the failure of node formation during the critical period of myelin development. Despite severely compromised axonal ensheathment and defective structure of node of Ranvier, the axonal diameter and density of axon in Qk-Nestin-iCKO mice were comparable with those in control mice (Figure 1—figure supplement 1I, J), and no evidence of axonal damage was detected in Qk-Nestin-iCKO mice via immunofluorescent staining of amyloid precursor protein (Figure 1I). In addition, we further asked if Qki loss impacts on the axon initial segment (AIS) structure. We found that the length of AIS labeled by AnkG at the proximal axon adjacent to the soma (NeuN) was not altered in the cortex region of Qk-Nestin-iCKO mice compared to control mice (Figure 1—figure supplement 1K–M), further suggesting that the integrity of the axon was not affected upon Qki depletion. Taken together, these data demonstrated that depletion of Qki in mouse NSCs results in severe neurological deficits due to hypomyelination in the CNS accompanied by the defect in node formation.

Qki loss in NSCs does not impair formation of OPCs or Aspa+Gstpi+ myelinating oligodendrocytes

Next, we sought to determine whether the hypomyelination observed in Qk-Nestin-iCKO mice was caused by a defect in the generation of OPCs from NSCs, impaired maturation from OPCs to oligodendrocytes, or a failure of myelinogenesis. Excluding the first possibility, we found that the number of Pdgfrα+ OPCs in the developing cortex tissues in Qk-Nestin-iCKO mice was slightly higher than that in control mice (Figure 2A), probably due to a compensatory increase in the proliferation of OPCs in response to hypomyelination. Notably, 92.6% of Pdgfrα+ OPCs in Qk-Nestin-iCKO mice lacked expression of Qki, indicating that Qki does not affect the generation or survival of OPCs. Excluding the second possibility above, immunofluorescent staining of Aspa and Gstpi, two well-established markers of mature oligodendrocytes, revealed that the numbers of Aspa+ and Gstpi+ mature oligodendrocytes in the corpus callosum tissues in Qk-Nestin-iCKO mice were comparable to those in control mice (Figure 2B, C). Also, co-immunofluorescent staining of Aspa and Gstpi demonstrated that they represent the same mature oligodendrocyte population (Figure 2D). The majority of these Aspa+ and Gstpi+ oligodendrocytes in Qk-Nestin-iCKO mice lacked expression of Qki (Figure 2B, C), indicating that OPCs without expression of Qki are still capable of differentiating into Aspa+Gstpi+ mature oligodendrocytes. Of note, we did not use another commonly used marker, CC-1, in our study because a recent study demonstrated that the CC-1 antibody actually recognizes Qki-7 (Bin et al., 2016), raising the concern that CC-1 is not a good marker for labeling mature oligodendrocyte in Qk-knockout mice. In fact, the number of CC-1+ mature oligodendrocytes in the corpus callosum tissues in Qk-Nestin-iCKO mice significantly decreased to 6.7% of that in control mice (Figure 2—figure supplement 1A), whereas the number of Aspa+Gstpi+ oligodendrocytes in Qk-Nestin-iCKO mice was similar to that in control mice. The reason for this phenomenon is that the Aspa+Gstpi+ oligodendrocytes in Qk-Nestin-iCKO mice cannot be recognized by CC-1 antibodies due to the absence of Qki-7 in these cells.

Figure 2. Qki loss in neural stem cells does not impair formation of oligodendrocyte precursor cells or Aspa+Gstpi+myelinating oligodendrocytes.

(A–C) Representative images of and quantification of immunofluorescent staining of Pdgfrα-Qki (A), Aspa-Qki (B), and Gstpi-Qki (C) in the corpus callosum tissues in Qk-Nestin-iCKO mice (n = 3) and control mice (n = 4) 2 weeks after tamoxifen injection. Scale bars, 50 μm. (D) Representative images of immunofluorescent staining of Gstpi and Aspa in the corpus callosum tissues in WT mice at 3 weeks of age (n = 4 mice/group). Scale bars, 50 μm. The Venn diagram depicts the overlap of Aspa+ and Gstpi+ oligodendrocytes. (E, F) RNA-seq expression data for Aspa transcripts from the databases of Gonçalo Castelo-Branco’s laboratory (E) and Ben A. Barres’s and Jiaqian Wu’s laboratory (F). VLMC: vascular and leptomeningeal cells; COP: differentiation-committed oligodendrocyte precursors; NFOL: newly formed oligodendrocytes; MFOL: myelin-forming oligodendrocytes; MOL: mature oligodendrocytes. (G) Representative images of immunofluorescent staining of Aspa in the corpus callosum regions in WT mice at 3 weeks of age. Scale bars, 50 μm. Data are shown as mean ± s.d. and were analyzed using one-way ANOVA with Tukey’s multiple comparisons test. **p<0.01; ****p<0.0001; ns: not significant.

Figure 2—source data 1. Exact p-values for statistical analysis.

Figure 2.

Figure 2—figure supplement 1. Qki loss in neural stem cells impairs the differentiation of Olig2+AspaGstpi- oligodendroglial lineage cells.

Figure 2—figure supplement 1.

(A, B) Representative images of and quantification of immunofluorescent staining of CC-1–Qki-5 (A) and Olig2-Qki (B) in the corpus callosum tissues in Qk-Nestin-iCKO mice (n = 3) and control mice (n = 4) 2 weeks after tamoxifen injection. Scale bars, 50 μm. Data are shown as mean ± s.d. and were analyzed using one-way ANOVA with Tukey’s multiple comparisons test. ***p<0.001; ****p<0.0001; ns: not significant. (C) Representative images of and quantification of TUNEL immunofluorescent staining in the corpus callosum tissues in Qk-Nestin-iCKO mice and control mice 2 weeks after tamoxifen injection (n = 4 mice/group). Scale bar, 50 μm. Data are shown as mean ± s.d. and were analyzed using Student's t test. ns: not significant.
Figure 2—figure supplement 2. Deletion of Qk in neural stem cells has no effects on neuronal or astrocytic populations.

Figure 2—figure supplement 2.

(A) Representative images of and quantification of immunofluorescent staining of NeuN in the cortex tissues in Qk-Nestin-iCKO mice and control mice 2 weeks after tamoxifen injection (n = 4 mice/group). Scale bars, 50 μm. Data are shown as mean ± s.d. and were analyzed using Student's t test. ns: not significant. (B) Representative images of and quantification of immunofluorescent staining of Sox9, GFP, and Gfap in the brain region within the red dotted box in Qk-Nestin-iCKO and control mice 2 weeks after tamoxifen injection (n = 3 mice/group). Scale bars, 100 μm. Data are shown as mean ± s.d. and were analyzed using Student's t test. ns: not significant.

Analyses of the previous transcriptomic studies (Marques et al., 2016; Zhang et al., 2014) revealed that the mRNA level of Aspa in myelinating oligodendrocytes was much higher than that in newly formed oligodendrocytes and OPCs (Figure 2E, F). In agreement with this, immunofluorescent staining of Aapa in the corpus callosum tissue in mice at P21 revealed expression of Aspa in myelin sheaths in addition to the cell bodies of oligodendrocytes (Figure 2G). Coupled with the observation that Aspa and Gstpi positivities represented the same mature oligodendrocyte population (Figure 2D), these data demonstrated that Aspa+Gstpi+ mature oligodendrocytes represent a subset of myelin-forming oligodendrocytes. Of note, the number of Olig2+ (marker of oligodendroglial lineage) cells in the corpus callosum tissues in Qk-Nestin-iCKO mice was 50.9% lower than that in control mice (Figure 2—figure supplement 1B), suggesting that Qki loss partially blocks OPCs differentiation into Olig2+Aspa-Gstpi- oligodendroglial lineage cells. Still, numbers of TUNEL positive cells were comparable between Qk-Nestin-iCKO and control (Figure 2—figure supplement 1C), suggesting that the survival of oligodendroglial lineage cells was not affected upon Qki depletion. Taken together, these data suggested that NSCs without expression of Qki are still capable of generating OPCs and subsequently differentiating into Aspa+Gstpi+ myelinating oligodendrocytes.

Nestin is expressed in NSCs, which can differentiate into neurons, astrocytes, and oligodendrocytes, so deletion of Qk in Qk-Nestin-iCKO mice potentially also affects neurons and astrocytes besides oligodendrocytes. Immunofluorescent staining of NeuN (a marker of neurons) revealed comparable numbers of neurons in the brains in Qk-Nestin-iCKO mice and control mice (Figure 2—figure supplement 2A). Notably, Sox9+Gfap+GFP+ astrocytes only constituted a small population among total Sox9+Gfap+ astrocytes in both Qk-Nestin-iCKO;mTmG mice (15.92%) and control Nestin-CreERT2;mTmG mice (16.22%) (Figure 2—figure supplement 2B), suggesting that the majority of Sox9+Gfap+ astrocytes are developed prior to P7 and therefore are not targeted by Nestin-CreERT2 inducible system with P7 tamoxifen treatment. Collectively, these data suggested that Qki loss in NSCs has minimal or no effect on the neuron and astrocyte populations in the brain, and hypomyelination induced by Qki loss is not secondary to defects in neurons or astrocytes.

Qki loss leads to defective myelin membrane assembly

The unexpected finding that Qk-Nestin-iCKO mice did not have reduced numbers of Aspa+Gstpi+ mature myelin-forming oligodendrocytes yet exhibited severe myelin defects (Figure 1) suggested that Qki loss impairs myelinating ability of Aspa+Gstpi+ oligodendrocytes without affecting the differentiation and survival of these cells. Consistent with previous studies demonstrating that Qki regulates the RNA homeostasis of myelin proteins, including MBP (Darbelli et al., 2016; Larocque et al., 2005; Larocque et al., 2002; Li et al., 2000; Zhao et al., 2010), we found that expression of MBP in the corpus callosum tissues was greatly reduced upon Qki depletion. In addition, unlike the homogeneous MBP staining in control mice, an uneven and patchy MBP staining pattern was detected in Qk-Nestin-iCKO mice (Figure 3A), implicating that MBP was not properly assembled in myelin sheaths other than a reduction in its expression. We also found that whereas MBP and PLP co-localized very well in the corpus callosum tissues in control mice, the MBP and PLP co-localization rate markedly decreased in Qk-Nestin-iCKO mice (45.7% vs. 88.5%; Figure 3B). Similarly, the MBP and MAG co-localization rate in Qk-Nestin-iCKO mice was substantially lower than that in control mice (26.9% vs. 75.1%; Figure 3C). Previous studies demonstrated that the proper interaction of myelin proteins such as PLP, MBP, and MAG with myelin lipids is required for formation of raft-like domains on myelin membrane, which is essential for myelin membrane assembly (Aggarwal et al., 2011; Ozgen et al., 2016; Saher et al., 2005; Simons et al., 2000). To determine whether defective myelin assembly in Qk-Nestin-iCKO mice was the result of abnormal myelin lipid component(s), we measured the myelin lipid level in the corpus callosum tissues via staining with FluoroMyelin, a lipophilic dye with high selectivity for myelin lipids (Monsma and Brown, 2012). The percentage of the FluoroMyelin+ area was 88.7% in control mice but only 6.6% in Qk-Nestin-iCKO mice (Figure 3D). More importantly, although the levels of both PLP and FluoroMyelin in Qk-Nestin-iCKO mice were lower than those in control mice, the ratio of FluoroMyelin to PLP in Qk-Nestin-iCKO mice was only about one fourth of that in control mice (Figure 3E), suggesting that the levels of myelin lipids were more profoundly reduced than were the levels of myelin proteins upon Qki depletion (Figure 1F, Figure 3D). Of note, the expression of Gstpi was strongly upregulated in the corpus callosum tissues of Qk-NSC-iCKO mice (Figure 2C). Since Gstpi has been implicated in stress response (Bartolini and Galli, 2016), we reasoned that Aspa+Gstpi+ mature oligodendrocytes in Qk-Nestin-iCKO mice might cope with imbalanced ratio of myelin lipids to myelin proteins by elevating Gstpi. Taken together, these data suggested that the myelin lipid components are disrupted by Qki loss in oligodendrocytes, which may consequently lead to defective assembly of myelin proteins with myelin lipids and inability to form compact myelin.

Figure 3. Qki loss leads to defective myelin membrane assembly.

Figure 3.

(A) Representative images of immunofluorescent staining of MBP in the corpus callosum tissues in Qk-Nestin-iCKO mice and control mice 2 weeks after tamoxifen injection. (B, C) Representative images of and quantification of the co-localization rates of immunofluorescent staining of MBP-PLP (B) and MBP-MAG (C) in the corpus callosum tissues in Qk-Nestin-iCKO mice and control mice 2 weeks after tamoxifen injection. (D) Representative images of and quantification of staining of FluoroMyelin in the corpus callosum tissues in Qk-Nestin-iCKO mice and control mice 2 weeks after tamoxifen injection. (E) Quantification of the relative ratio of FluoroMyelin to PLP in the corpus callosum tissues in Qk-Nestin-iCKO mice (n = 3) and control mice (n = 4) 2 weeks after tamoxifen injection. Scale bars, 50 μm. Data are shown as mean ± s.d. and were analyzed using Student's t test. The r values in the scatter plots (B, C) were calculated using Pearson’s correlation. ****p<0.0001.

Figure 3—source data 1. Exact p-values for statistical analysis.

Qki depletion in OPCs leads to defective myelinogenesis without impairing differentiation of Aspa+ myelinating oligodendrocytes

To further confirm that dysmyelination in Qk-Nestin-iCKO mice was oligodendroglial lineage cell-autonomous, mice bearing the Qk-loxP allele were bred with mice bearing the Plp1-CreERT2 transgene, in which expression of tamoxifen-inducible Cre is under the control of the Plp1 promoter (Figure 4A). Because the activity of the Plp1 promoter in the CNS of early neonatal mice is restricted to a subset of OPCs poised to differentiate into myelinating oligodendrocytes (Guo et al., 2009), tamoxifen administration in Plp1-CreERT2;QkL/L pups at P4 (hereafter denoted as ‘Qk-Plp-iCKO mice’) enabled us to delete Qk in this subset of OPCs (Figure 4A). All Qk-Plp-iCKO mice began to experience tremors and ataxia about 11 days after tamoxifen injection, and they gradually displayed reduced coordinate movement, marked growth retardation, hunched posture, and paralysis before dying about 18 days after tamoxifen injection (Figure 4B–E, Figure 4—figure supplement 1A, Video 2), whereas the control mice (including Plp1-CreERT2;Qk+/+, Plp1-CreERT2;QkL/+, and QkL/L littermates) did not exhibit neurological symptoms after tamoxifen injection at P4.

Figure 4. Qk deletion in oligodendrocyte precursor cells leads to defective myelinogenesis without impairing differentiation of Aspamyelinating oligodendrocytes.

(A) Schema of the generation of Qk-Plp-iCKO mice. (B) Representative images of severe hind limb paresis in Qk-Plp-iCKO mice 2 weeks after tamoxifen injection. (C) Latency of mice falling off the rotarod at a constant speed (5 rpm). n = 3 mice in the Qk-Plp-iCKO group; n = 7 mice in the control group. (D) Body weights of Qk-Plp-iCKO mice (n = 12) and control mice (n = 18) 2 weeks after tamoxifen injection. (E) Kaplan–Meier curves of and log-rank test results for overall survival in Qk-Plp-iCKO mice (n = 32) and control mice (n = 59). (F) Representative images of and quantification of immunofluorescent staining of MBP, GFP, and Iba1 in the corpus callosum tissues in Qk-Plp-iCKO mice (n = 6) and control mice (n = 3) 2 weeks after tamoxifen injection. Scale bars, 50 μm. (G) Representative images of and quantification of staining of FluoroMyelin in the corpus callosum tissues in Qk-Plp-iCKO mice (n = 3) and control mice (n = 4) 2 weeks after tamoxifen injection. Scale bars, 50 μm. (H) Representative electron micrographs of and quantification of the percentage of myelinated axons in the optic nerves in Qk-Plp-iCKO mice (n = 3) and control mice (n = 5) 2 weeks after tamoxifen injection. Scale bars, 500 nm. (I) Representative images of and quantification of immunofluorescent staining of Aspa and Qki in the corpus callosum tissues in Qk-Plp-iCKO mice (n = 3) and control mice (n = 4) 2 weeks after tamoxifen injection. Scale bars, 50 μm. Data are shown as mean ± s.d. and were analyzed using Student's t test (C,D, F–H) or one-way ANOVA with Tukey’s multiple comparisons test (I). **p<0.01; ****p<0.0001; ns: not significant.

Figure 4—source data 1. Exact p-values for statistical analysis.

Figure 4.

Figure 4—figure supplement 1. Deletion of Qk in mouse oligodendrocyte precursor cells results in hypomyelination in the central nervous system.

Figure 4—figure supplement 1.

(A) Kaplan–Meier curves of and log-rank test results for quaking phenotype-free survival of QkL/L mice (n = 8), Plp-CreERT2;WT mice (n = 8), Plp-CreERT2;QkL/+ mice (n = 43), and Plp-CreERT2;QkL/L mice (n = 32). (B) Representative electron micrographs of and quantification of the g-ratio in the optic nerves in Qk-Plp-iCKO mice (n = 3) and control mice (n = 5) 2 weeks after tamoxifen injection. Scale bars, 2 μm. (C–E) Quantification of the g-ratio (C) axonal diameter (D) and density of axon (E) in the mice in (B). Data are shown as mean ± s.d. and were analyzed using Student's t test. *p<0.05; ns: not significant. (F) Representative images of and quantification of immunofluorescent staining of GFP and Pdgfrα in the cortex tissues in Qk-Plp-iCKO;mTmG mice (n = 6) and control Plp-CreERT2;mTmG mice (n = 3) 2 weeks after tamoxifen injection. Scale bar, 50 μm. Data are shown as mean ± s.d. and were analyzed using Student's t test. ns: not significant.
Figure 4—figure supplement 2. Deletion of Qk does not alter proliferation of oligodendrocyte precursor cells and oligodendroglial lineage cells.

Figure 4—figure supplement 2.

(A, B) Representative images of and quantification of immunofluorescent staining of Pdgfrα and Ki67 (A) and Olig2 and Ki67 (B) in the brain region within the red dotted box in Qk-Plp-iCKO;mTmG mice (n = 6 in A and n = 4 in B) and control Plp-CreERT2;mTmG mice (n = 6 in A and n = 4 in B) 2 weeks after tamoxifen injection. Scale bar, 50 μm. Data are shown as mean ± s.d. and were analyzed using Student's t test. ns: not significant. Arrow indicates Pdgfrα+Ki67+ cells (A) and Olig2+Ki67+ cells (B).

Video 2. Defect in motor coordination displaying tremors and ataxia in Qk-Plp-iCKO mice.

Download video file (12.7MB, mp4)

Similar to that observed in Qk-Nestin-iCKO mice, expression of MBP in the corpus callosum tissues in Qk-Plp-iCKO mice 2 weeks after tamoxifen injection (in all subsequent experiments unless specified otherwise) was significantly lower than the robust expression in control mice (Figure 4F). In addition, the percentage of the GFP+ area in the corpus callosum tissues in Qk-Plp-iCKO;mTmG mice markedly decreased relative to that in control Plp-CreERT2;mTmG mice (5.0% vs. 20.5%; Figure 4F), confirming a hypomyelinating phenotype in Qk-Plp-iCKO mice. As a secondary response to hypomyelination, three-fold greater accumulation of Iba1+ microglia in the corpus callosum tissues in Qk-Plp-iCKO mice than in control mice was observed (Figure 4F). Of note, the percentage of the FluoroMyelin+ area was 63.3% in control mice but only 35.2% in Qk-Plp-iCKO mice (Figure 4G). Ultrastructural analysis of the optic nerves further revealed that when compared with control mice Qk-Plp-iCKO mice exhibited a substantially lower percentage of myelinated axons (56.7% vs. 70.4%; Figure 4H) and a significantly larger g-ratio (0.86 vs. 0.82; Figure 4—figure supplement 1B, C) but a comparable axonal diameter and density of axon (Figure 4—figure supplement 1D, E).

The hypomyelinating phenotype in Qk-Plp-iCKO mice could be due to compromised oligodendrocyte differentiation or defective myelinogenesis. To determine the effect of Qki on OPC development, we first confirmed that Plp1-CreERT2;mTmG cohort labels a subset of OPC population as indicated by the Pdgfrα+GFP+ double-positive cells (Figure 4—figure supplement 1F), and Qki loss did not alter the number of Pdgfrα+GFP+ cells (Figure 4—figure supplement 1F). Furthermore, no alteration in proliferation was observed upon Qki depletion in the OPC population (Pdgfrα+ cells) and oligodendroglial lineage cells (Olig2+ cells) as indicated by the co-labeling of a proliferating marker, Ki67 (Figure 4—figure supplement 2A, B). In addition, comparable numbers of TUNEL positive cells (which are very few) were found between Qk-Nestin-iCKO and control (Figure 2—figure supplement 1C). These data suggest that the development and survival of OPC population was not altered upon Qki depletion. In addition to the intact OPC survival, the number of Aspa+ mature oligodendrocytes in the corpus callosum tissues in Qk-Plp-iCKO mice was comparable to that in control mice, similar to the finding observed in Qk-Nestin-iCKO mice (Figure 2B), indicating that OPCs with Qki depletion can still differentiate into Aspa+ mature oligodendrocytes (Figure 4I). Taken together, these data demonstrated that the hypomyelination induced by Qki depletion in OPCs is attributable to defective myelinogenesis but not OPC survival and oligodendrocyte differentiation.

Qki regulates transcription of the genes involved in myelin cholesterol biosynthesis

To investigate the underlying mechanisms by which Qki regulates myelinogenesis, transcriptomic profiling (RNA sequencing [RNA-seq]) of the brains in Qk-Plp-iCKO mice and control littermates was performed. Overall, expression of 673 and 692 genes in Qk-Plp-iCKO mice was significantly lower and higher than those in control mice, respectively (fold change >1.2; p<0.05). Ingenuity pathway analysis (IPA) revealed that the canonical pathways affected most by Qki depletion were cholesterol biosynthesis, mevalonate pathway, zymosterol biosynthesis, and geranylgeranyl diphosphate biosynthesis (Figure 5A, B), which are all associated with de novo cholesterol biosynthesis pathway. Similarly, transcriptomic analyses of the brains of Rosa26-CreERT2;QkL/L mice and control mice that were treated with tamoxifen at P1 and collected at P7 revealed that lipid metabolism pathways, particularly concentration of sterol and concentration of cholesterol, were among the biological processes most affected by Qki depletion (Figure 5—figure supplement 1A). Consistently, IPA-based upstream regulator analysis revealed that Qki loss led to inactivation of Srebp2 and Srebp cleavage-activating protein (Scap) as well as activation of insulin-induced gene 1 protein (Insig1), which inhibits Srebp2 function by interacting with Scap to retard the Scap/Srebp complex in the endoplasmic reticulum (Figure 5C). Hence, transcription of multiple Srebp2 target genes encoding the enzymes involved in cholesterol biosynthesis, including hydroxymethylglutaryl-CoA synthase 1 (Hmgcs1), 3-hydroxy-3-methylglutaryl-CoA reductase (Hmgcr), farnesyl diphosphate synthase (Fdps), and lanosterol synthase (Lss), was strongly diminished by Qki depletion (Figure 5D). In agreement with the observation in Qk-Plp-iCKO mice, quantitative real-time PCR (qPCR) analysis confirmed reduced transcription of these genes involved in cholesterol biosynthesis in Qk-Nestin-iCKO mice (Figure 5E).

Figure 5. Qki regulates transcription of the genes involved in myelin cholesterol biosynthesis.

(A) Bar graph showing the five canonical pathways most affected by Qki on the basis of differentially expressed genes in Qk-Plp-iCKO mice and control mice (n = 2 mice/group). Blue and red indicate pathways whose activity decreased or increased, respectively, in Qk-Plp-iCKO mice. (B) Overlapping canonical pathway networks for the top 20 canonical pathways with a minimum of three common molecules in different pathways. GGPP: geranylgeranyl diphosphate. (C) Bar graph showing the 10 upstream regulators most enriched in Qk-Plp-iCKO mice. (D) Schema of the cholesterol biosynthesis pathway. (E) Quantification of expression of representative enzymes involved in cholesterol biosynthesis in the corpus callosum tissues in Qk-Nestin-iCKO mice and control mice 2 weeks after tamoxifen injection according to real-time qPCR (n = 4 mice/group). (F, G) Representative images of and quantification of immunofluorescent staining of Hmgcs1 (F) and Fdps (G) in Aspa+Qki- oligodendrocytes in the corpus callosum of Qk-Nestin-iCKO mice (n = 3) and Aspa+Qki+ oligodendrocytes in the corpus callosum of control mice (n = 4) 2 weeks after tamoxifen injection. Scale bars, 50 μm. (H) Immunoblots of and quantification of the levels of expression of the representative enzymes involved in cholesterol biosynthesis in the corpus callosum tissues in Qk-Nestin-iCKO mice and control mice 2 weeks after tamoxifen injection (n = 3 mice/group). (I) Quantification of the cholesterol levels in the corpus callosum tissues in Qk-Nestin-iCKO mice (n = 6) and control mice (n = 5) 2 weeks after tamoxifen injection. Data are shown as mean ± s.d. and were analyzed using Student's t test. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.

Figure 5—source data 1. Exact p-values for statistical analysis.

Figure 5.

Figure 5—figure supplement 1. Qki regulates transcription of the genes involved in myelin cholesterol biosynthesis.

Figure 5—figure supplement 1.

(A) Graph of the five enriched molecular and cellular functions most affected by Qki on the basis of differentially expressed genes in Rosa26-CreERT2;QkL/L mice (n = 3 mice) and control mice (n = 5 mice), shown in the left panel, with the individual annotation of lipid metabolism shown in the right panel. (B, C) Representative images of and quantification of immunofluorescent staining of Hmgcs1 (B) and Fdps (C) in Aspa+Qki- oligodendrocytes in the corpus callosum of Qk-Plp-iCKO mice (n = 3) and Aspa+Qki+ oligodendrocytes in the corpus callosum of control mice (n = 4) 2 weeks after tamoxifen injection. Scale bars, 50 μm. Data are shown as mean ± s.d. and were analyzed using Student's t test. ***p<0.001; ****p<0.0001.

Verifying reduced expression of enzymes involved in cholesterol biosynthesis upon Qki loss, we found that the levels of Hmgcs1 and Fdps proteins, which were measured using immunofluorescent staining in Aspa+Qki- oligodendrocytes in the corpus callosum tissues in Qk-Nestin-iCKO mice, were only 11.2% and 12.7% of those in Aspa+Qki+ oligodendrocytes in control mice, respectively (Figure 5F, G). Similarly, the levels of Hmgcs1 and Fdps proteins in Aspa+Qki- oligodendrocytes in the corpus callosum tissues in Qk-Plp-iCKO mice were only 20.2% and 31.2% of those in Aspa+Qki+ oligodendrocytes in control mice, respectively (Figure 5—figure supplement 1B, C). Of note, the levels of Hmgcs1 and Fdps in Aspa+Qki+ oligodendrocytes in both Qk-Nestin-iCKO mice and Qk-Plp-iCKO mice were similar to those in control mice (Figure 5F, G, Figure 5—figure supplement 1B, C), indicating that expression of Hmgcs1 and Fdps reduced by Qki depletion is oligodendrocyte-autonomous. The lower expression of Hmgcs1, Hmgcs2, Hmgcr, Fdps, and Lss in Qk-Nestin-iCKO mice than in control mice at the protein level was further confirmed via immunoblotting (Figure 5H). As a consequence of reduced expression of enzymes involved in cholesterol biosynthesis, Qk-Nestin-iCKO mice exhibited dramatically lower concentrations of both free cholesterol and cholesteryl ester in the corpus callosum tissues than did control mice (Figure 5I). Taken together, these data suggested that Qki regulates transcription of enzymes involved in cholesterol biosynthesis in oligodendrocytes and controls synthesis of this rate-limiting building block of myelinogenesis during development.

Qki-5 cooperates with Srebp2 to regulate cholesterol biosynthesis

Srebp2 is the major transcription factor that regulates expression of the genes involved in cholesterol biosynthesis and import (Horton et al., 2002). Besides lower global expression of the genes involved in cholesterol biosynthesis in Qki-depleted oligodendrocytes than in control oligodendrocytes, we found that Srebp2 and its regulatory partners (Scap and Insig1) were the upstream regulators of these differentially expressed genes (Figure 5C). Immunofluorescent staining revealed that expression of Srebp2 in Aspa+ oligodendrocytes was similar in Qk-Nestin-iCKO mice and control mice (Figure 6A), indicating that transcriptional activity but not expression of Srebp2 may be suppressed by Qki loss in oligodendrocytes. On the basis of our previous observation that the nuclear-localized Qki isoform, Qki-5 was predominantly localized to chromatin and functions as a co-activator of PPARβ-RXRα complex to transcriptionally regulate fatty acid metabolism in oligodendrocytes in adult mouse brain, which is essential for the maintenance of mature myelin homeostasis (Zhou et al., 2020), we hypothesized that Qki-5 regulates transcription of the genes involved in cholesterol biosynthesis by interacting with Srebp2 during myelin development of young mice when cholesterol biosynthesis is highly active. Accordingly, reciprocal co-immunoprecipitation (co-IP) assays performed using oligodendrocytes that differentiated from NSCs revealed a robust interaction between Qki-5 and Srebp2 (Figure 6B–D).

Figure 6. Qki-5 interacts with Srebp2 to regulate transcription of the genes involved in cholesterol biosynthesis.

(A) Representative images of and quantification of immunofluorescent staining of Srebp2 in Aspa+Qki- oligodendrocytes in Qk-Nestin-iCKO mice (n = 3) and Aspa+Qki+ oligodendrocytes in control mice (n = 4) 2 weeks after tamoxifen injection. Scale bars, 50 μm. (B) Results of co-immunoprecipitation (co-IP) using an anti–Qki-5 antibody with differentiated oligodendrocytes followed by detection of Srebp2 via immunoblotting. (C) Results of co-IP using an anti-Srebp2 antibody with differentiated oligodendrocytes followed by detection of Qki-5 via immunoblotting. (D) Results of co-IP using an anti-Flag antibody with differentiated oligodendrocytes having ectopic expression of Flag-Srebp2 followed by detection of Qki-5 via immunoblotting. (EF) ChIP-seq density heat maps (E) and average genome-wide occupancies (F) of Qki-5, Srebp2, and Pol II in differentiated oligodendrocytes. Regions within 2.5 kb of the transcriptional start site (TSS) are included. All events are rank-ordered from high to low Qki-5 occupancy. (G) Venn diagram of the overlap of Qki-5-, Srebp2-, and Pol II-binding events in the promoter regions in differentiated oligodendrocytes. Promoters are defined as TSS ±2 kb. (H) Canonical pathway analysis of Qki-5-, Srebp2-, and Pol II-co-occupied genes in differentiated oligodendrocytes. Cellular pathways involved in cholesterol biosynthesis are labeled in dark pink. (I) Representative ChIP-seq binding events of Qki-5, Srebp2, and Pol II in the promoter regions of the genes involved in cholesterol biosynthesis. y-axis: normalized reads. (J) ChIP-qPCR results showing the recruitment of Qki-5, Srebp2, and Pol II to the promoter regions of Hmgcs1 and Hmgcr in differentiated oligodendrocytes. Data are shown as mean ± s.d. and were analyzed using Student’s t test. ****p<0.0001; ns: not significant.

Figure 6—source data 1. Exact p-values for statistical analysis.

Figure 6.

Figure 6—figure supplement 1. Qki-5 cooperates with Srebp2 to regulate transcription of the genes involved in cholesterol biosynthesis.

Figure 6—figure supplement 1.

(A) Global distribution of the ChIP-seq events of Qki-5, Srebp2, and Pol II in differentiated oligodendrocytes. UTR: untranslated region. (B) Venn diagram of the overlap of Qki-5-bound genes in Qki-5 ChIP-seq from differentiated oligodendrocytes and genes with substantially lower expression in Qk-Plp-iCKO mice than in control mice according to RNA-seq. (C) Canonical pathway analysis of the 277 overlapping genes shown in (B). Cellular pathways involved in cholesterol biosynthesis are labeled in magenta. (D) Sequence motifs enriched in Qki-5 ChIP-seq data from differentiated oligodendrocytes by HOMER motif analysis. (E) Canonical pathway analysis of Srebp2-bound genes in differentiated oligodendrocytes. Cellular pathways involved in cholesterol biosynthesis are labeled in blue. (F) Representative ChIP-seq binding events of Qki-5, Srebp2, and Pol II in the promoter regions of the genes involved in cholesterol biosynthesis in WT and Qk-/- differentiated oligodendrocytes. y-axis: normalized reads. 

To determine whether the molecular interaction between Qki-5 and Srebp2 in oligodendrocytes impacts transcriptional control of the genes involved in cholesterol biosynthesis, we performed chromatin IP (ChIP) combined with high-throughput DNA sequencing (ChIP-seq) using differentiated oligodendrocytes with antibodies against Qki-5 and Srebp2. We identified 17,709 peaks for Qki-5 ChIP-seq and 957 peaks for Srebp2 ChIP-seq. Genomic distribution analyses revealed that 50.11% and 82.27% of Qki-5- and Srebp2-binding events were enriched in the promoter regions, respectively (Figure 6—figure supplement 1A). Notably, the promoter/transcriptional start site (TSS)-binding occupancies of Qki-5 and Srebp2 strongly correlated with each other (Figure 6E, F). Specifically, 88.73% of total Srebp2-binding events (811 of 914) in the promoter regions overlapped with Qki-5-binding events (Figure 6G). Furthermore, ChIP-seq analysis of RNA polymerase II (Pol II), an indicator of transcriptionally active sites, revealed that 99.75% of the overlapping binding events between Qki-5 and Srebp2 (809 of 811) were co-occupied by Pol II (Figure 6G), suggesting that the Qki-5 and Srebp2 form a complex that regulates transcription.

Canonical pathway analysis of genes bound by Qki-5, Srebp2, and Pol II (n = 809) (Figure 6G) revealed that the cholesterol biosynthesis pathway was the most enriched cellular pathway potentially regulated by transcriptional collaboration between Qki-5 and Srebp2 (Figure 6H). The promoter regions of the genes involved in cholesterol biosynthesis, such as Hmgcs1, Hmgcr, Fdps, cytochrome P450, family 51 (Cyp51), and methylsterol monoxygenase 1 (Msmo1), were co-occupied by Qki-5, Srebp2, and Pol II (Figure 6I). Consistently, ChIP-qPCR confirmed that Qki-5, Srebp2, and Pol II were highly enriched in the promoter regions of Hmgcs1 and Hmgcr (Figure 6J). Taken together, these data suggested that transcriptional cooperation between Qki-5 and Srebp2 regulates cholesterol biosynthesis.

Because Qki-5 binds to a large number of the promoter regions genome-wide, we further sought to identify the specific cellular pathways in oligodendrocytes directly regulated by Qki at transcriptional level during myelin formation. Canonical pathway analysis of 194 overlapping genes among 5885 Qki-5-bound genes in anti-Qki-5 ChIP-seq of freshly isolated mouse oligodendrocytes (Zhou et al., 2020) and 673 significantly downregulated genes in Qk-Plp-iCKO mice revealed that cholesterol biosynthesis was the most enriched pathway (Figure 7A, B). This was also consistent for the overlapping genes among Qki-5-bound genes in differentiated oligodendrocytes and the significantly downregulated genes in Qk-Plp-iCKO mice (Figure 6—figure supplement 1B, C). This analysis suggested that the Qki-5/Srebp2 complex predominantly regulates expression of the genes involved in cholesterol biosynthesis. Of note, multiple transcription factors such as NF1/CTF, Sox10, C/EBPα, Rfx1, and Nrf1 were enriched as potential binding partners for Qki-5 based on the motif analysis using Qki-5 ChIP-seq data (Figure 6—figure supplement 1D). These transcription factors potentially play important roles in regulating their target genes by cooperating with Qki-5. However, most of the target genes under control of these transcription factors are not altered at the gene expression level in oligodendrocytes. Still, this result provides an important future perspective in studying the function of Qki in transcriptional regulation in other cell types/other tissues.

Figure 7. Qki transcriptionally enhances Srebp2-mediated cholesterol biosynthesis.

Figure 7.

(A) Venn diagram of the overlap of Qki-5-bound genes in Qki-5 ChIP-seq from freshly isolated mouse oligodendrocytes and the genes with markedly lower expression in Qk-Plp-iCKO mice than in control mice. DE: differentially expressed. (B) Canonical pathway analysis of the 194 overlapping genes shown in (A). Cellular pathways involved in cholesterol biosynthesis are labeled in magenta. (C) Average occupancies of Qki-5, Srebp2, and Pol II in the gene clusters bound by Srebp2 (n = 914) in differentiated oligodendrocytes. Regions within 2.5 kb of the transcriptional start site (TSS) are included. (D, E) Average occupancies of Srebp2 (D) and Pol II (E) in the gene clusters bound by Srebp2 in WT and Qk-/- differentiated oligodendrocytes (left) and comparison of ChIP-seq (right). Regions within 2.5 kb of the TSS are included. RPM: reads counts per million mapped reads; RPKM: reads counts per kilobase per million mapped reads. (F) Bar graphs of the RPM of the Srebp2 ChIP-seq peaks within ± 0.5 kb from the TSS for 17 well-characterized Srebp2 target genes involved in cholesterol biosynthesis in WT and Qk-/- differentiated oligodendrocytes. (G) Representative ChIP-seq binding events of Qki-5, Srebp2, and Pol II in the promoter regions of the genes involved in cholesterol biosynthesis in WT and Qk-/- differentiated oligodendrocytes. y-axis: normalized reads. (H) ChIP-qPCR results showing the recruitment of Srebp2 to the promoter regions of Hmgcs1 and Hmgcr in WT and Qk-/- differentiated oligodendrocytes. Data are shown as mean ± s.d. and were analyzed using Student’s t test. ***p<0.001; ****p<0.0001; ns: not significant.

Figure 7—source data 1. Exact p-values for statistical analysis.

To determine how Qki-5 transcriptionally enhances Srebp2-mediated cholesterol biosynthesis, we performed ChIP-seq with WT and Qki-depleted differentiated oligodendrocytes using antibodies against Qki-5, Srebp2, and Pol II. Because Srebp2-bound genes were mostly involved in cholesterol biosynthesis (Figure 6—figure supplement 1E), to further examine the molecular alteration upon Qki depletion, we focused on the gene clusters bound by Srebp2, which were strongly co-occupied by Qki-5, Srebp2, and Pol II in their promoter regions (Figure 7C). Notably, occupancies of Srebp2 (725 of 914) and Pol II (894 of 914) in the promoter regions were strikingly reduced upon Qki depletion (Figure 7D, E). Particularly, the promoter occupancy of Srebp2 on all 17 target genes enriched in cholesterol biosynthesis according to IPA analysis (Figure 6—figure supplement 1E) such as Msmo1, Hmgcs1, Cyp51, isopentenyl-diphosphate delta isomerase 1 (Idi1), squalene epoxidase (Sqle), and Hmgcr was globally reduced upon Qki depletion (Figure 6—figure supplement 1FFigure 7F, G). ChIP-qPCR further confirmed reduced recruitment of Srebp2 to the promoter regions of Hmgcs1 and Hmgcr upon Qki depletion (Figure 7H). Taken together, these data suggested that Qki-5 transcriptionally activates Srebp2-mediated cholesterol biosynthesis in oligodendrocytes, which is essential for proper myelin formation during brain development.

Discussion

Timely onset of oligodendrocyte myelination is essential for brain development (Armati and Mathey, 2010). Cholesterol is an important functional component of myelin formation, and deficiency in cholesterol biosynthesis is associated with various hypomyelinating diseases reported in human genetic studies (Nwokoro et al., 2001; Porter and Herman, 2011). Brain cholesterol production mainly depends on de novo synthesis to fulfill the high demand for cholesterol due to the restriction of cholesterol entry into the brain by the blood-brain barrier. However, how cholesterol biosynthesis is regulated in oligodendrocytes, the primary myelinating cells in the CNS, is not clear. The present study revealed that Qki functions as a novel transcriptional co-activator of Srebp2 in oligodendrocytes to ensure supply of cholesterol for proper developmental myelination in a timely manner (Figure 8).

Figure 8. Model of Qki’s roles in regulating cholesterol biosynthesis and fatty acid metabolism during central nervous system myelination and myelin maintenance.

Figure 8.

Qki regulates cholesterol biosynthesis in a Srebp2-dependent manner during de novo myelinogenesis but not during myelin maintenance. In contrast, Qki regulates fatty acid metabolism during both de novo myelinogenesis and mature myelin maintenance.

Previous studies showed that cholesterol biosynthesis is highly active during the early stage of brain development (Dietschy and Turley, 2004). However, the cell types primarily responsible for cholesterol biosynthesis in myelin formation were not clear. In the present study, we observed that Aspa and Gstpi were co-expressed with Srebp2, Fdps, and Hmgcs1 in oligodendrocytes, suggesting that Aspa+Gstpi+ cells represent a subset of myelinating oligodendrocytes with highly active cholesterol biosynthesis (Figure 5F, G). Aspa has been shown to be more abundantly expressed in myelinating oligodendrocytes than in premyelinating oligodendrocytes (Marques et al., 2016; Zhang et al., 2014). Additionally, Canavan disease caused by Aspa deficiency is accompanied by myelin deficiency with reduced level of myelin lipids, including cholesterol, as Aspa enzymatically produces acetate as a source of acetyl-CoA, a precursor for synthesis of cholesterol (Madhavarao et al., 2005). These lines of evidence, in combination with our observations, suggest that Aspa+Gstpi+ cells represent a subset of myelinating oligodendrocytes. In addition to oligodendrocytes, previous studies reported that cholesterol generated by astrocytes also contributes to myelination (Camargo et al., 2017). However, the uptake of cholesterol from astrocytes was not sufficient to compensate for the reduced cholesterol synthesis in oligodendrocytes with deletion of Scap (Camargo et al., 2017), Fdft1 (Saher et al., 2005), or Qk (current study), indicating that oligodendrocytes are the major cell types producing cholesterol for myelination during early development.

Previous studies showed that qkv mice had reduced myelin lipid content, including cholesterol (Baumann et al., 1968; Singh et al., 1971). This phenomenon was previously thought to be secondary to loss of mature oligodendrocytes in qkv mice during development. However, in the present study, we uncovered a previously uncharacterized function of Qki in controlling transcription of the genes involved in cholesterol biosynthesis without affecting the differentiation of Aspa+Gstpi+ myelinating oligodendrocytes. Further studies are needed to elucidate how Aspa+Gstpi+ oligodendrocytes specifically regulate cholesterol biosynthesis and how other cell types, including astrocytes, contribute to oligodendroglial myelination.

During the characterization of oligodendroglial lineage cell populations, we observed that the differentiation of Aspa+Gstpi+ myelinating oligodendrocytes was not impaired upon Qki depletion, but their cholesterol biosynthesis was severely defective. Previous studies showed that all three isoforms of Qki are essential for the differentiation and maturation of oligodendrocytes (Chen et al., 2007; Darbelli et al., 2016; Larocque et al., 2005). Specifically, the number of Olig2+ oligodendroglial lineage cells in QKIFL/FL;Olig2–Cre mice was about 50% lower than that in control mice (Darbelli et al., 2016). Therefore, we also checked whether oligodendroglial lineage cell populations other than Aspa+Gstpi+ myelinating oligodendrocytes were affected by Qki loss in our Qk-Nestin-iCKO mice. We found that the number of Olig2+ cells was reduced by 50.9% in Qk-Nestin-iCKO mice compared to that in control mice (Figure 2—figure supplement 1B), suggesting that Qki loss affects OPCs differentiation into Olig2+Aspa-Gstpi- oligodendroglial lineage cells, whose function is unclear. Collectively, we found that Qki plays variable roles in the differentiation of different subpopulations of oligodendrocyte lineage cells, leading to an intriguing question what determines the specific roles of Qki during oligodendrocyte differentiation and myelinogenesis, which needs to be further investigated.

Mammalian Quaking (Qk) undergoes alternative splicing to express the RNA-binding proteins Qki-5, Qki-6, and Qki-7 (Darbelli and Richard, 2016). In the current study, we showed that Qki-5 is required for transcriptional activation of Srebp2-mediated cholesterol biosynthesis in oligodendrocytes. Notably, we observed that expression of myelin proteins such as MBP, PLP, and MAG was greatly reduced upon Qki depletion (Figure 1F). Although we did not find these proteins to be direct transcriptional targets of Qki-5 and Srebp2, the stability and nuclear export of MBP mRNA may be regulated by Qki-6 and Qki-7 as shown in qkv mice, where expression of Qki-6 and Qki-7 is predominantly depleted (Larocque et al., 2002; Li et al., 2000). Another nonmutually exclusive explanation of decreased expression of MBP is that the reduction in cholesterol level induced by Qki depletion potentially leads to destabilization of myelin because protein:lipid ratio is crucial for proper integration of proteins and lipids in myelin membrane (Aggarwal et al., 2011; Ozgen et al., 2016; Saher et al., 2005; Simons et al., 2000), which is shown by the defect in co-localization of different myelin proteins (Figure 3B). Although we showed that Qki-5 transcriptionally regulates cholesterol biosynthesis, it is still unclear if Qki-6 and Qki-7 also play a role in the enhancement of cholesterol biosynthesis pathway by regulating mRNA of cholesterol biosynthesis-related genes as we observed more significant decrease of these genes at the protein level compared to the mRNA level (Figure 5E–H). Therefore, further investigation is needed to determine the specific roles of different Qki isoforms during oligodendrocyte differentiation and myelinogenesis in early brain developmental stages.

Previous studies showed that cholesterol biosynthesis in oligodendrocytes and Schwann cells could be regulated by transcriptional regulators such as Tcf7l2, Chd8, and Maf (Kim et al., 2018; Zhao et al., 2016; Zhao et al., 2018). However, how Srebp2, the master transcription factor in cholesterol biosynthesis, is regulated in oligodendrocytes is unclear. In the present study, we demonstrated that Qki-5 functions as a co-activator of Srebp2 to enhance transcription of the genes involved in cholesterol biosynthesis in myelinating oligodendrocytes and that depletion of Qki leads to reduced promoter occupancy of Srebp2 and Pol II and decreased transcription of the genes involved in cholesterol biosynthesis (Figure 7). Further studies are needed to determine how Qki enhances transcriptional activity of Srebp2.

In this study, we found that Qki-5 functions as a co-activator of Srebp2 to regulate transcription of the genes involved in cholesterol biosynthesis, which is essential for proper myelinogenesis during development. Although cholesterol biosynthesis was the major downstream of Qki-5, we noticed that the molecular functions related to fatty acid metabolism, concentration of fatty acid, and synthesis of fatty acid were also markedly inhibited after Qki depletion in neonatal mice (Figure 5—figure supplement 1A). We assume that both disturbed cholesterol biosynthesis and fatty acid metabolism upon Qki depletion contributed to the hypomyelination and neurological deficits of Qk-iCKO mice during development (Figure 8). Interestingly, our recent study demonstrated that Qki-5 forms a complex with PPARβ-RXRα and coactivates transcription of the genes for fatty acid metabolism, which is essential for the maintenance of mature myelin homeostasis (Zhou et al., 2020Figure 8). However, continuous biosynthesis of cholesterol may not be necessary to maintain the homeostasis of mature myelin, probably due to the very slow turnover of myelin cholesterol in adult rodents (Ando et al., 2003; Smith, 1968Figure 8). It remains unclear what is the determinant factor of Qki-5 interaction and co-activation of Srebp2 or PPARβ-RXRα on the chromatin under different contexts including the brains from mice of different ages, and whether Qki-5 can interact with other transcription factors. Taken together, the universal occupancy of Qki-5 on chromatin greatly expands our understanding of Qki itself, as well as the biology of transcriptional control by an RNA-binding protein.

Notably, we observed that Qki was depleted in nearly all Pdgfrα+ OPCs (92.6%) in Qk-Nestin-iCKO mice (Figure 2A), which led to the question of how most of the OPCs were targeted under the control of Nestin-Cre after birth. Cortically derived OPCs are considered to make up about 80% of all OPCs in the cortex, which are called late-born OPCs because they arise as a third wave of OPCs initiating at birth and reaching maximum in number 2–4 weeks after birth in mice (van Tilborg et al., 2018). This population of OPCs is known to replace the OPCs originating at embryonic stages in the forebrain (Bergles and Richardson, 2015), suggesting an active generation of OPCs from NSCs during the first month after birth, potentially leading to highly efficient Qki depletion in NSC-derived Pdgfrα+ OPCs in our study. On the basis of these findings, it is not difficult to understand that although Qki was efficiently depleted in OPCs of Qk-Plp-iCKO mice at P4 and P5, an active generation of WT OPCs from WT NSCs diluted the OPC pool, leading to Qki depletion in only a subset of OPCs in Qk-Plp-iCKO mice at P18 (Figure 4I). Thus, although both Qk-Nestin-iCKO mice and Qk-Plp-iCKO mice showed dysmyelinating phenotype, Qk-Nestin-iCKO mice exhibited a more severe phenotype than did Qk-Plp-iCKO mice.

In this study, the median survival duration in Qk-Nestin-iCKO mice was 13 days after tamoxifen injection due to severe dysmyelination, yet in our previous study (Shingu et al., 2017), Qk-Nestin-iCKO mice could survive through adulthood. We believe that the difference in the survival times between these two cohorts of Qk-Nestin-iCKO was due to the background of the mice. In the present study, the mice were on a pure C57BL/6J background, whereas the mice in the previous study were on a mixed C57BL/6J and FVB background. OPCs have been shown to repopulate as a third wave of cortically arising OPCs from NSCs initiating at birth and reaching the maximum number around 2–4 weeks after birth (van Tilborg et al., 2018). However, the exact time point of this wave of OPC generation can be greatly influenced by the mouse background (van Tilborg et al., 2018), resulting in highly variable Qk deletion in OPCs with P7 injection of tam in Qk-Nestin-iCKO cohorts of different backgrounds.

Effort has been made to treat hypomyelinating disorders such as SLOS, Pelizaeus–Merzbacher disease, and Charcot–Marie–Tooth disease type 1A with dietary supplementation of lipids, including cholesterol (Fledrich et al., 2018; Saher et al., 2012; Tierney et al., 2010). However, challenges still remain, as cholesterol rarely crosses the blood-brain barrier, and long-term benefits of cholesterol supplementation have not been clearly examined (Tierney et al., 2010). Whether dietary supplementation of cholesterol can rescue hypomyelination in Qk-iCKO mice would be interesting to know. Of note, we previously demonstrated that Qki plays an important role in intracellular vesicle trafficking in NSCs (Shingu et al., 2017). If the same function of Qki exists in oligodendrocytes, cholesterol transport and uptake would be impaired due to defective intracellular vesicle trafficking in Qki-depleted oligodendrocytes, which may lead to inefficiencies in high-cholesterol diet-based therapy. The present findings will potentially provide understanding of brain-specific cholesterol biosynthesis and shed light on mechanism-based therapeutics for enhancing oligodendrocyte myelination. As QKI is one of the genes most associated with various neurological diseases (Darbelli and Richard, 2016), understanding the mechanisms underpinning Qki/Srebp2-mediated cholesterol biosynthesis and myelination will help identify tissue-specific therapeutic opportunities for neurological diseases associated with myelin defects (Nwokoro et al., 2001; Porter and Herman, 2011).

Materials and methods

Key resources table.

Reagent type
(species)
or resource
Designation Source or reference Identifiers Additional information
Antibody Mouse monoclonal anti-MBP BioLegend Cat# SMI-94R
Antibody Mouse monoclonal anti–β-Amyloid BioLegend Cat# SIG-39220
Antibody Rabbit polyclonal anti-PLP Abcam Cat# ab105784
Antibody Goat polyclonal anti-Iba1 Abcam Cat# ab107159
Antibody Rabbit polyclonal anti-Hmgcs1 Abcam Cat# ab155787
Antibody Rabbit polyclonal anti-Fdps Abcam Cat# ab153805  
Antibody Rabbit polyclonal anti-Lss Abcam Cat# ab80364
Antibody Mouse monoclonal anti-RNA polymerase II CTD repeat YSPTSPS Abcam Cat# ab817
Antibody Rabbit monoclonal anti-MAG Cell Signal Technology Cat# 9043
Antibody Rabbit polyclonal anti-GFP Cell Signal Technology Cat# 2555
Antibody Rabbit monoclonal anti-Pdgfrα Cell Signal Technology Cat# 3174
Antibody Mouse monoclonal
anti-Ki67
Cell Signal Technology Cat# 9449
Antibody Rabbit polyclonal anti-Aspa Millipore Cat# ABN1698
Antibody Rabbit polyclonal anti-Olig2 Millipore Cat# AB9610
Antibody Mouse monoclonal anti-NeuN Millipore Cat# MAB377
Antibody Mouse monoclonal anti-Apc (CC-1) Millipore Cat# OP80
Antibody Rabbit polyclonal anti-Gstpi MBL International Cat# 311
Antibody Mouse monoclonal anti-Qki (Pan) Sigma-Aldrich Cat# SAB5201536
Antibody Rabbit polyclonal anti-Hmgcs2 Sigma-Aldrich Cat# SAB2107997  
Antibody Rabbit polyclonal anti-Srebp2 Sigma-Aldrich Cat# HPA031962  
Antibody Mouse monoclonal antiβ-actin Sigma-Aldrich Cat# A5441  
Antibody Mouse monoclonal anti-Flag Sigma-Aldrich Cat# F1804  
Antibody Rabbit polyclonal anti-Hmgcr Thermo Fisher Scientific Cat# PA5-37367
Antibody Rabbit polyclonal anti-Srebp2 Cayman Chemical Cat# 10007663
Antibody Mouse monoclonal anti-Gfap BD Biosciences Cat# 556330
Antibody Normal rabbit IgG Santa Cruz Technology Cat# sc-2027
Antibody Rabbit polyclonal antiQki-5 This paper immunized with a short synthetic peptide (CGAVATKVRRHDMRVHPYQRIVTADRAATGN)
Antibody Mouse monoclonal anti-AnkG Sigma-Aldrich MABN466
Antibody Rabbit polyclonal antiSox9 Sigma-Aldrich AB5535
Antibody Rabbit polyclonal
anti-Caspr
Gift from Dr. Rasband lab
Antibody Mouse monoclonal
anti-PanNav
Gift from Dr. Rasband lab (K58/35)
Chemical compound Tamoxifen Sigma-Aldrich Cat# T5648
Chemical compound 4-hydroxytamoxifen Sigma-Aldrich Cat# H7904
Chemical compound Poly-L-ornithine Sigma-Aldrich Cat# P3655
Chemical compound 3,3',5-Triiodo-L-thyronine Sigma-Aldrich Cat# T2877
Chemical compound Anti-Flag M2 Magnetic Beads Sigma-Aldrich Cat# M8823
Chemical compound Citrate buffer Poly Scientific R&D Corp Cat# s2506
Chemical compound FluoroMyelin Red Thermo Fisher Scientific Cat# F34652
Chemical compound Penicillin-Streptomycin Thermo Fisher Scientific Cat# 15140122
Recombinant protein Laminin Mouse Protein, Natural Thermo Fisher Scientific Cat# 23017015
Chemical compound Neurobasal Medium Thermo Fisher Scientific Cat# 21103049
Chemical compound B-27 Thermo Fisher Scientific Cat# 17504044
Chemical compound GlutaMAX Supplement Thermo Fisher Scientific Cat# 35050061
Chemical compound Puromycin Dihydrochloride Thermo Fisher Scientific Cat# A1113802
Recombinant protein Dynabeads Protein G Thermo Fisher Scientific Cat# 10004D
Chemical compound HardSet Antifade Mounting Medium with DAPI Vector Laboratories Cat# H1500
Chemical compound NeuroCult Basal Medium Stemcell Technologies Cat# 05700
Chemical compound NeuroCult Proliferation Supplement Stemcell Technologies Cat# 05701
Recombinant protein Recombinant Human EGF ProteinTech Cat# AF-100-15
Recombinant protein Recombinant Human FGF-basic (146 a.a.) ProteinTech Cat# 100-18C
Chemical compound DNase (RNase-free) Qiagen Cat# 79254
Chemical compound cOmplete, Mini Protease Inhibitor Cocktail Roche Diagnostics Cat# 11836153001
Chemical compound RNase A Thermo Fisher Scientific Cat# 12091021
Chemical compound Proteinase K (PK) Solution Promega Cat# MC5005
Commercial
assay
Neural Tissue Dissociation Kit Miltenyi Biotec Cat# 130-092-628
Commercial
assay
In-Fusion HD Cloning Plus Takara Bio Cat# 638910
Commercial
assay
RNeasy Mini Kit Qiagen Cat# 74104
Commercial
assay
QIAquick PCR Purification Kit Qiagen Cat# 28104
Commercial
assay
SuperScript III First-Strand Synthesis SuperMix for qRT-PCR Thermo Fisher Scientific Cat# 11752250
Commercial
assay
SuperSignal West Pico PLUS Chemiluminescence System Thermo Fisher Scientific Cat# 34579
Commercial
assay
iTaq Universal SYBR Green Supermix Bio-rad Laboratories Cat# 1725122
Commercial
assay
DC Protein Assay Kit Bio-rad Laboratories Cat# 5000121
Commercial
assay
Total Cholesterol Assay Kits Cell Biolabs Cat# STA-390
Commercial
assay
KAPA Hyper Prep Kit Kapa Biosystems Cat# 004477
Commercial
assay
In Situ Cell Death
Detection Kit
Millipore
Sigma
11684795910
Deposited data Gene expression profile This paper GEO: GSE145116
Deposited data Gene expression profile This paper GEO: GSE145117
Deposited data ChIP sequencing data This paper GEO: GSE144756
Deposited data ChIP sequencing data Zhou et al., 2020 GEO: GSE126577
Experimental model Mouse: B6.(Cg)-Nestin-CreERT2 Imayoshi et al., 2008 N/A
Experimental model Mouse: B6.(Cg)-Plp1-CreERT2 The Jackson Laboratory Stock No.: 005975
Experimental model Mouse: B6.129-Rosa26-CreERT2 The Jackson Laboratory Stock No.: 008463
Experimental model Mouse: B6.129(Cg)-ROSAmT/mG The Jackson Laboratory Stock No.: 007676
Experimental model Mouse: B6.(Cg)-Qk-loxP Shingu et al., 2017 N/A
Recombinant
DNA reagent
pLKO-puro Flag-Srebp2 Addgene Cat# 32018
Recombinant
DNA reagent
pLKO-puro 3X Flag-Srebp2 This paper N/A
Software and
algorithm
ImageJ National Institutes of Health https://imagej.nih.gov/ij/
Software and
algorithm
HISAT2 Johns Hopkins University https://ccb.jhu.edu/software/hisat2/index.shtml
Software and
algorithm
StringTie Johns Hopkins University https://ccb.jhu.edu/software/stringtie/
Software and
algorithm
DESeq2 Bioconductor http://bioconductor.org/packages/DESeq2/
Software and
algorithm
IPA Qiagen https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis/
Software and
algorithm
Trim Galore Babraham Institute http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/
Software and
algorithm
Bowtie Johns Hopkins University http://bowtie-bio.sourceforge.net/tutorial.shtml
Software and
algorithm
SAMtools Li et al., 2009 https://github.com/samtools/samtools
Software and
algorithm
MACS2 Feng et al., 2012 https://github.com/taoliu/MACS/
Software and
algorithm
deeptools Ramírez et al., 2016 https://github.com/deeptools/deepTools
Software and
algorithm
ngsplot Shen et al., 2014 https://github.com/shenlab-sinai/ngsplot
Software and
algorithm
Prism 8 GraphPad Software https://www.graphpad.com/scientific-software/prism/
Software and
algorithm
HOMER UCSD http://homer.ucsd.edu/homer

Mouse models

Nestin-CreERT2 mice (C57BL/6) were gifts from R. Kageyama (Kyoto University, Kyoto, Japan) (Imayoshi et al., 2008). Plp-CreERT2 mice (C57BL/6) (Doerflinger et al., 2003), Rosa26-CreERT2 mice (C57BL/6) (Ventura et al., 2007), and mTmG mice (C57BL/6) (Muzumdar et al., 2007) were obtained from The Jackson Laboratory (Bar Harbor, ME). Conditional Qk-knockout mice with two loxP sequences flanking exon 2 of the Qk gene (QkL/L) were generated by our group as described previously (Shingu et al., 2017). QkL/L mice were crossed with Nestin-CreERT2 transgenic mice, Plp-CreERT2 transgenic mice, or R26-CreERT2 mice, in which expression of tamoxifen-inducible Cre was under the control of the Nestin promoter, Plp promoter, or Gt(ROSA)26Sor promoter, respectively. Mice were group-housed at MD Anderson’s animal facility under pathogen-free conditions, maintained under a 12 hr light-dark schedule, allowed free access to water and food, and monitored for signs of illness every other day. All mouse experiments were conducted according to the NIH guidelines, and protocols (IACUC Study #00001392-RN01) for mouse procedures were approved by the Institutional Animal Care and Use Committee of The University of Texas MD Anderson Cancer Center.

Beginning at P7, Nestin-CreERT2;QkL/L mice were injected subcutaneously with 20 μL of tamoxifen (10 mg/mL) (Sigma-Aldrich) for two consecutive days to induce the deletion of Qk. Littermates (Nestin-CreERT2;QkL/+ mice, Nestin-CreERT2;WT mice, or QkL/L mice) of the same age and genetic background were also injected with tamoxifen and used as controls for further experiments. Beginning at P4, Plp-CreERT2;QkL/L, Plp-CreERT2;QkL/+ mice, Plp-CreERT2;WT mice, and QkL/L mice were injected subcutaneously with 10 μL of tamoxifen (10 mg/mL) for two consecutive days. After tamoxifen injection, the experimental mice were monitored daily, and their neurological impairments were recorded for further plotting of a quaking phenotype-free survival curve. When the Qk-iCKO mice reached the clinical endpoint, they had severe paralysis, significant weight loss, and hunched posture and were near death. Thus, they were euthanized for humanistic care.

Rotarod behavioral analysis

The tamoxifen-injected mice were trained for five trials at a constant 5 rpm using a rotarod apparatus (Harvard Bioscience) and then tested in a 120 s trial at a constant 5 rpm. The latency of mice of falling off the rotarod was recorded. If a mouse stayed on the rotarod for more than 120 s, it was recorded as 120 s. Three trials were tested for each mouse at intervals of at least 30 min. Statistical analysis was performed using the mean latency of mice falling off the rotarod of three trials.

Tissue preparation and immunofluorescence

Mice were anesthetized with isoflurane and transcardially perfused with 20 mL of 4% paraformaldehyde in phosphate-buffered saline (PBS). Their brains and optic nerves were dissected, postfixed in 4% paraformaldehyde at 4°C for 2 days, dehydrated in 30% sucrose in PBS at 4°C until the tissues sank, and embedded in optimal cutting temperature compound. Alternatively, brains and optic nerves were postfixed in formalin at room temperature for 2 days and embedded in paraffin. Frozen sections of 10 μm and paraffin-embedded sections of 5 μm were quickly boiled in citrate buffer (Poly Scientific R&D Corp.) for heat-induced epitope retrieval. They were then permeabilized with 0.25% Triton for 10 min and blocked with 10% horse serum for 1 hr at room temperature. The following primary antibodies were used for staining of the sections overnight at 4°C: anti-MBP (SMI-94R) and anti-β-amyloid (SIG-39220) were from BioLegend; anti-PLP (ab105784), anti-Iba1 (ab107159), anti-Hmgcs1 (ab155787), and anti-Fdps (ab153805) were from Abcam; anti-MAG (#9043), anti-GFP (#2555), anti-Pdgfrα (#3174), and anti-Ki67 (#9449) were from Cell Signaling Technology; anti-Aspa (ABN1698), anti-Olig2 (AB9610), anti-NeuN (MAB377), and anti–CC-1 were from Merck Millipore; anti-Gstpi (311) was from MBL International; anti-Qki (SAB5201536), anti-AnkG (MABN466), anti-Sox9 (AB5535), and anti-Srebp2 (HPA031962) were from Sigma-Aldrich and Millipore Sigma; and anti-Gfap (556330) was from BD Biosciences; anti-Caspr and anti-PanNav (K58/35) were gifts from Matthew N. Rasband (Baylor College of Medicine, Houston, TX, USA). TUNEL positive cells were detected using In Situ Cell Death Detection Kit (11684795910) from Millipore Sigma. The sections were incubated with appropriate Alexa Fluor dye-conjugated secondary antibodies (Thermo Fisher Scientific) for 1 hr at room temperature. FluoroMyelin (Thermo Fisher Scientific) was stained directly onto rehydrated slides for 20 min at room temperature according to the manufacturer’s instructions. The sections were mounted using a VECTASHIELD antifade mounting medium with DAPI. A Leica DMi8 microscope was used to visualize most of the stained sections, and a Leica DFC345 FX digital monochrome camera was used to obtain fluorescent images of them. The images in Figure 2C and Figure 2—figure supplement 1A were taken using a Nikon Upright Eclipse Ni-E microscope.

Electron microscopy

Beginning at P7, Nestin-CreERT2;QkL/L mice (n = 3) and control mice (n = 3) were injected with 20 μL of tamoxifen (10 mg/mL) on two consecutive days. Also, beginning at P4, Plp-CreERT2;QkL/L mice (n = 3) and control mice (n = 5) were injected with 10 μL of tamoxifen (10 mg/mL) on two consecutive days. Two weeks later, these experimental mice were transcardially perfused with 2% paraformaldehyde. Their optic nerves were then postfixed in a cold PBS solution containing 3% glutaraldehyde and 2% paraformaldehyde at 4°C and processed at the MD Anderson High Resolution Electron Microscopy Facility. In brief, these fixed optic nerves were washed in 0.1 M sodium cacodylate buffer, treated with 0.1% Millipore-filtered cacodylate-buffered tannic acid, postfixed with 1% buffered osmium tetroxide for 30 min, and stained en bloc with 1% Millipore-filtered uranyl acetate. The samples were dehydrated in increasing concentrations of ethanol and then infiltrated with and embedded in LX-112 medium. The samples were polymerized in a 60°C oven for about 3 days. Ultrathin sections of the samples were cut using a Leica Ultracut microtome, stained with uranyl acetate and lead citrate in a Leica EM stainer, and examined using a JEM 1010 transmission electron microscope (JEOL USA) at an accelerating voltage of 80 kV. Digital images of the sections were captured using an AMT imaging system (Advanced Microscopy Techniques). ImageJ software (National Institutes of Health) was used to measure the axonal calibers and diameters of myelinated fibers; the percentage of myelinated axons, g-ratio, axonal diameter, and density of axon in these optic nerves were quantified on the basis of these measurements.

NSC isolation and oligodendrocyte differentiation

The entire brains of Nestin-CreERT2;QkL/L mouse pups at P1 were dissected, sliced into small pieces, and dissociated enzymatically into single cells using Neural Tissue Dissociation Kits (Miltenyi Biotec) according to the manufacturer’s instructions. The single-cell suspension was then maintained in NeuroCult Basal Medium (STEMCELL Technologies) containing NeuroCult Proliferation Supplement (STEMCELL Technologies), 20 ng/mL epidermal growth factor (ProteinTech), 10 ng/mL basic fibroblast growth factor (ProteinTech), 50 U/mL penicillin G (Thermo Fisher Scientific), and 50 μg/mL streptomycin (Thermo Fisher Scientific) in a humidified 37°C incubator with 5% CO2. All the cell cultures were negative for mycoplasma infection. To knock out Qk, NSCs mentioned above were treated twice with 100 nM 4-hydroxytamoxifen (Sigma-Aldrich) at 2-day intervals.

To induce in vitro oligodendrocyte differentiation, NSCs were seeded onto culture dishes precoated with 20 μg/mL poly-L-ornithine (Sigma-Aldrich) and 10 μg/mL laminin (Thermo Fisher Scientific) at 2.5 × 104 cells/cm2 and cultured in the NSC medium described above. Two days later, the medium was changed to Neurobasal Medium (Thermo Fisher Scientific) supplemented with B-27 (Thermo Fisher Scientific), 2 mM GlutaMAX-I (Thermo Fisher Scientific), 30 ng/mL 3,3',5-triiodo-L-thyronine (Sigma-Aldrich), 50 U/mL penicillin G, and 50 μg/mL streptomycin. The cells were cultured in differentiation medium for 3 days, and fresh medium was replaced every other day.

Stable cells

The coding DNA sequence region of Srebf2 was amplified from pLKO-puro Flag-Srebp2 (Peterson et al., 2011) using PCR and engineered into a pcDNA vector containing 2X Flag to generate an insert of Srebp2 with 2X Flag at the N-terminus of Srebp2 (pcDNA-2X Flag-Srebp2). pLKO-puro Flag-Srebp2 containing 1X Flag at the N-terminus was cut using SalI and NotI to remove Srebp2, and pcDNA-2X Flag-Srebp2 was fused with the cut vector to generate an Srebp2-expressing vector with 3X Flag at the N-terminus (pLKO-puro 3X Flag-Srebp2) using an In-Fusion HD Cloning Kit (Takara Bio). Lentiviruses were packaged in HEK293T cells and used to infect NSCs. The cells were then selected with puromycin (Thermo Fisher Scientific) for 1 week, and the viable cells were used for further experiments.

RNA isolation and real-time qPCR

After tamoxifen administration at P7, Nestin-CreERT2;QkL/L mice and control mice were sacrificed at P21 to dissect the corpus callosum tissues (n = 4/group). Total RNA was extracted from those corpus callosum tissues using an RNeasy Mini Kit (QIAGEN) following the manufacturer’s instructions. Two micrograms of total RNA were used to generate cDNA using an SuperScript III First-Strand Synthesis SuperMix (Thermo Fisher Scientific) . Real-time qPCR was carried out using a 7500 Fast Real-Time PCR system (Applied Biosystems) with iTaq Universal SYBR Green Supermix (Bio-Rad Laboratories). The quantitative transcription levels of the genes involved in cholesterol biosynthesis were normalized to expression of Actb and calculated using the ΔΔCT method. A complete list of the sequences of the primer pairs used is shown in Supplementary file 1.

RNA-seq and pathway enrichment analyses

Rosa26-CreERT2;QkL/L mice (n = 3) and control mice (n = 5) at P1 were injected with 10 μL of tamoxifen (10 mg/mL) and killed at P7 to collect their brains. Beginning at P7, Plp-CreERT2;QkL/L mice (n = 2) and control mice (n = 2) were injected with 20 μL of tamoxifen (10 mg/mL) on two consecutive days, and they were sacrificed at P30 to collect their brains. Total RNA was isolated from their brains using an RNeasy Mini Kit with DNase treatment (RNase-free; QIAGEN). RNA-seq was performed by the Illumina HiSeq/MiSeq sequencing service at the MD Anderson Advanced Technology Genomics Core. The procedure of stranded paired-end RNA-seq analysis was performed according to Pertea’s protocol (Pertea et al., 2016). In brief, the paired end reads were aligned with the mouse reference genome (mm10) and mouse reference transcriptome (GENCODE vM8) using HISAT2 software (Kim et al., 2015) with the parameter ‘--rna-strandness RF --dta --no-mixed --no-discordant.’ Gene expression levels were then calculated using StringTie software (Pertea et al., 2015) with GENCODE vM8 annotations of basic chromosomes. After the read counts were obtained using prepDE.py (Pertea et al., 2015), analysis of differential expression was conducted using DESeq2 (Love et al., 2014). The threshold for identifying differentially expressed genes was set at 1.5-fold (R26 cohort) or 1.2-fold (Plp cohort) with p values less than 0.05. IPA software (QIAGEN) (Krämer et al., 2014) was used to analyze the significantly affected canonical signaling pathways, molecular and cellular functions, and upstream regulators associated with differentially expressed genes after Qki depletion.

Cholesterol measurement

The corpus callosum tissues in Qk-Nestin-iCKO mice (n = 6) and control mice (n = 5 mice) were homogenized in a lipid extraction buffer (chloroform:isopropanol:NP-40, 7.0:11.0:0.1). After centrifugation at 13,000 g at 4°C for 10 min, the supernatant was collected and air-dried to remove the organic solvent. Dried lipid was used to measure cholesterol levels using Total Cholesterol Assay Kits (Cell Biolabs).

IP and immunoblotting

The differentiated oligodendrocytes were washed once with PBS and cross-linked with 1% formaldehyde for 10 min. After quenching with 0.125 M glycine, cells were washed twice with cold PBS and lysed in NP-40 buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 0.05% NP-40 supplemented with freshly added protease inhibitors) for 30 min at 4°C. The whole-cell lysate was then sonicated using a Bioruptor Pico sonication device (Diagenode) for 60 cycles (30 s on, 30 s off) on high-power setting. After centrifugation at 13,000 g at 4°C for 15 min to remove insoluble debris, the supernatant was incubated with antibodies against Qki-5 (immunizing rabbit with a short synthetic peptide [CGAVATKVRRHDMRVHPYQRIVTADRAATGN]; GenScript), Srebp2 (10007663; Cayman Chemical), or normal rabbit immunoglobulin G at 4°C overnight. The IP system was further rotated in the presence of magnetic recombinant protein G-coated beads (Thermo Fisher Scientific) for 2 hr at 4°C. Alternatively, co-IP was performed as described above except using anti-Flag M2 magnetic beads (Sigma-Aldrich) for 4 hr, and co-IP using denatured anti-FLAG M2 magnetic beads which were boiled at 95°C for 30 min was served as a control. Bound beads were then washed three times in cold NP-40 buffer by inverting the tubes, boiled in sample buffer at 95°C for 20 min, and subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting.

Corpus callosum tissue lysates were prepared by homogenizing the tissue in NP-40 buffer at 4°C as described above and quantified using a DC protein assay (Bio-Rad Laboratories) prior to immunoblotting. Briefly, 20–40 μg of proteins was electrophoresed on 4–12% gradient sodium dodecyl sulfate-polyacrylamide gels and transferred to nitrocellulose membranes. Subsequently, the membranes were blocked with 5% milk at room temperature for 1 hr and incubated with anti-Hmgcs1 (ab155787; Abcam), anti-Hmgcs2 (SAB2107997; Sigma-Aldrich), anti-Hmgcr (PA5-37367; Thermo Fisher Scientific), anti-Lss (ab80364; Abcam), anti-Fdps (ab153805; Abcam), anti-Flag (F1804; Sigma-Aldrich), and anti-β-actin (A5441; Sigma-Aldrich) antibodies overnight at 4°C. Membranes were then incubated with appropriate horseradish peroxidase-conjugated secondary antibodies, and the bands were visualized using a SuperSignal enhanced chemiluminescence system (Thermo Fisher Scientific). Blots were processed and quantified using ImageJ software, and β-actin was used for normalization.

ChIP-seq and ChIP-qPCR

The ChIP assays were performed as described previously (Lan et al., 2007). In brief, adherent differentiated oligodendrocytes were cross-linked with 1% formaldehyde at room temperature for 10 min and quenched by 0.125 M glycine. Then, the cross-linked cells were suspended in ChIP lysis buffer (50 mM Tris-HCl, pH 7.4, 500 mM NaCl, 2 mM EDTA, 1% Triton X-100, 0.1% sodium dodecyl sulfate, 0.1% sodium deoxycholate with freshly added protease inhibitors). Sheared chromatin from these cells was diluted in ChIP dilution buffer (50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 2 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate with freshly added protease inhibitors) at a ratio of 1:1 and then incubated with anti–Qki-5 (immunizing rabbit with a short synthetic peptide [CGAVATKVRRHDMRVHPYQRIVTADRAATGN]; GenScript), anti-Srebp2 (10007663; Cayman Chemical), or anti-Pol II (ab817; Abcam) antibodies overnight at 4°C. After immobilization on prewashed protein G agarose beads (Thermo Fisher Scientific), the protein-DNA complexes were washed three times with high-salt buffer (50 mM HEPES, pH 7.4, 500 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% sodium dodecyl sulfate with freshly added protease inhibitors), twice with low-salt buffer (10 mM Tris-HCl, pH 8.1, 250 mM LiCl, 1 mM EDTA, 0.5% NP-40, 0.5% sodium deoxycholate with freshly added protease inhibitors), and once with TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA). Elution and reverse cross-linking of DNA were carried out using elution buffer (50 mM Tris-HCl, pH 8.0, 10 mM EDTA, 1% sodium dodecyl sulfate) at 65°C for 4 hr. After digestion with RNase A (Thermo Fisher Scientific) and proteinase K (Promega) for 1 hr at 55°C, DNA samples were purified using a PCR Purification Kit (QIAGEN). Library preparation was performed using a KAPA HyperPrep Kit (Kapa Biosystems) according to the manufacturer’s instructions and sequenced using an Illumina HiSeq X Ten system (Jiangxi Haplox Clinical Lab Cen, Ltd). FASTQ data were trimmed using Trim Galore (v0.4.4_dev) and mapped to the mouse genome (mm10 version) using Bowtie2 (v2.3.4.1) (Langmead and Salzberg, 2012) with the parameters ‘−1 R1.fastq −2 R2.fastq -X 1000’, then the PCR duplication was removed by SAMtools (v1.8) (Li et al., 2009). Peaks were identified by MACS2 (v2.1.2) with the parameters ‘macs2 callpeak -f BAMPE -g mm -q 0.05 -t ChIP.bam -n NAME -c INPUT.bam’ (Feng et al., 2012). Bedgraph files were generated by deeptools (v3.3.0) (Ramírez et al., 2016) and uploaded to UCSC browser for visualization. Signal plots and heatmaps were generated using ngsplot (Shen et al., 2014). ChIP-seq was normalized by total reads. Motifs enriched in Qki-5 peaks were identified by HOMER (v4.10.1) with the following parameters: findMotifsGenome.pl peaklist.bed mm10 –size given –len 6,8,10,12,14 –mis 2 (Heinz et al., 2010). IPA software (Krämer et al., 2014) was used to analyze canonical signaling pathways enriched in genes whose promoters were co-occupied by Qki-5, Srebp2, and Pol II; overlapping genes among Qki-5-bound genes in freshly isolated mouse oligodendrocytes according to ChIP-seq and significantly downregulated genes in Qk-Plp-iCKO mice according to RNA-seq; overlapping genes among Qki-5-bound genes in differentiated oligodendrocytes according to ChIP-seq and significantly downregulated genes in Qk-Plp-iCKO mice according to RNA-seq; Srebp2-bound genes from Srebp2 ChIP-seq. ChIP-qPCR was performed using a 7500 Fast Real-Time PCR system (Applied Biosystems) with iTaq Universal SYBR Green Supermix (Bio-Rad Laboratories). All qPCRs were performed in triplicate, and a complete list of the sequences of the primers used is shown in Supplementary file 1.

Statistics and reproducibility

All statistical analyses were performed using Prism 8 (GraphPad Software). No statistical methods were used for predetermining the sample size. The sample size was based on experimental feasibility, sample availability, and the number of necessary to obtain definitive results. The number of animals in each experiment is described in the corresponding figure legends. Numerical results are presented as means, with error bars representing standard deviation (s.d.). For comparison of two groups, a two-tailed, unpaired Student's t test was used. To compare three or more groups, one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons test was conducted. Animal survival durations were analyzed using the log-rank test. Data distribution was assumed to be normal but has not been formally tested. All values of p < 0.05 were considered significant. No randomization or blinding events occurred during the experiments.

Acknowledgements

We thank Shan Jiang, Kun Zhao, and Yanping Cao for mouse husbandry and care and all members of the Hu laboratory for helpful discussions. We thank Kenneth Dunner, Jr. for performing electron microscopy studies. We also thank Scientific Publications, Research Medical Library at MD Anderson for editorial assistance. This investigation was supported in part by grants from National Cancer Institute (R37CA214800) and the Cancer Prevention and Research Institute of Texas (RP120348 and RP170002). This research was supported by the University Cancer Foundation via the Institutional Research Grant program at the University of Texas MD Anderson Cancer Center. JH is supported by The University of Texas Rising STARs Award, the Sidney Kimmel Scholar Award, the Sontag Foundation Distinguished Scientist Award, and the Brockman Foundation. SS is supported by the Russell and Diana Hawkins Family Foundation Discovery Fellowship, Sam Taub and Beatrice Burton Endowed Fellowship in Vision Disease, and Roberta M and Jean M Worsham Endowed Fellowship.

Funding Statement

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Contributor Information

Jian Hu, Email: JHu3@mdanderson.org.

Marianne E Bronner, California Institute of Technology, United States.

Jian Xu, University of Texas Southwestern Medical Center, United States.

Funding Information

This paper was supported by the following grants:

  • NCI R37CA214800 to Jian Hu.

  • University of Texas MD Anderson Cancer Center startup to Jian Hu.

  • Cancer Prevention and Research Institute of Texas RP120348 to Jian Hu.

  • Cancer Prevention and Research Institute of Texas RP170002 to Jian Hu.

Additional information

Competing interests

No competing interests declared.

Author contributions

Conceptualization, Data curation, Formal analysis, Validation, Visualization, Methodology, Writing - original draft, Writing - review and editing.

Conceptualization, Data curation, Formal analysis, Validation, Visualization, Methodology, Writing - original draft, Writing - review and editing.

Formal analysis, Visualization, Methodology, Writing - review and editing.

Resources.

Methodology.

Resources.

Resources.

Diagram illustration.

Resources.

Genotyping.

Software, Formal analysis.

Resources, Formal analysis, Writing - review and editing.

Resources, Formal analysis, Writing - review and editing.

Conceptualization, Supervision, Funding acquisition, Investigation, Writing - review and editing.

Ethics

Animal experimentation: All mouse experiments were conducted in accordance with protocols approved by the MD Anderson Institutional Animal Care and Use Committee. (IACUC Study #00001392-RN01).

Additional files

Supplementary file 1. A complete list of the sequences of the primer pairs used in this study.
elife-60467-supp1.docx (44.1KB, docx)
Transparent reporting form

Data availability

Sequencing data have been deposited in GEO under accession codes GSE145116, GSE145117 and GSE144756.

The following datasets were generated:

Zhou X, Shin S, He C, Zhang Q, Ren J, Dai C, Shingu T, Yuan L, Wang Y, Chen Y, Lan F, Hu J. 2021. RNA-seq-1. NCBI Gene Expression Omnibus. GSE145116

Zhou X, Shin S, He C, Zhang Q, Ren J, Dai C, Shingu T, Yuan L, Wang Y, Chen Y, Lan F, Hu J. 2021. RNA-seq-2. NCBI Gene Expression Omnibus. GSE145117

Zhou X, Shin S, He C, Zhang Q, Ren J, Dai C, Shingu T, Yuan L, Wang Y, Chen Y, Lan F, Hu J. 2021. Genome-wide maps of Qki-5, Srebp2, and Pol II in oligodendrocyte. NCBI Gene Expression Omnibus. GSE144756

The following previously published dataset was used:

Zhou X, He C, Ren J, Dai C, Stevens SR, Wang Q, Zamler D, Shingu T, Yuan L, Chandregowda CR, Wang Y, Ravikumar V, Rao A, Zhou F, Zheng H, Rasband MN, Chen Y, Lan F, Heimberger AB, Segal BM, Hu J. 2020. Genome-wide maps of Qki-5 and PPARb in mouse oligodendrocytes. NCBI Gene Expression Omnibus. GSE126577

References

  1. Aggarwal S, Yurlova L, Simons M. Central nervous system myelin: structure, synthesis and assembly. Trends in Cell Biology. 2011;21:585–593. doi: 10.1016/j.tcb.2011.06.004. [DOI] [PubMed] [Google Scholar]
  2. Ando S, Tanaka Y, Toyoda Y, Kon K. Turnover of myelin lipids in aging brain. Neurochemical Research. 2003;28:5–13. doi: 10.1023/a:1021635826032. [DOI] [PubMed] [Google Scholar]
  3. Armati PJ, Mathey EK. The Biology of Oligodendrocytes. Cambridge University Press; 2010. [DOI] [Google Scholar]
  4. Bartolini D, Galli F. The functional interactome of GSTP: a regulatory biomolecular network at the interface with the Nrf2 adaption response to oxidative stress. Journal of Chromatography B. 2016;1019:29–44. doi: 10.1016/j.jchromb.2016.02.002. [DOI] [PubMed] [Google Scholar]
  5. Baumann NA, Jacque CM, Pollet SA, Harpin ML. Fatty acid and lipid composition of the brain of a myelin deficient mutant, the "quaking" mouse. European Journal of Biochemistry. 1968;4:340–344. doi: 10.1111/j.1432-1033.1968.tb00216.x. [DOI] [PubMed] [Google Scholar]
  6. Bergles DE, Richardson WD. Oligodendrocyte development and plasticity. Cold Spring Harbor Perspectives in Biology. 2015;8:a020453. doi: 10.1101/cshperspect.a020453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bin JM, Harris SN, Kennedy TE. The oligodendrocyte-specific antibody 'CC1' binds Quaking 7. Journal of Neurochemistry. 2016;139:181–186. doi: 10.1111/jnc.13745. [DOI] [PubMed] [Google Scholar]
  8. Camargo N, Goudriaan A, van Deijk AF, Otte WM, Brouwers JF, Lodder H, Gutmann DH, Nave KA, Dijkhuizen RM, Mansvelder HD, Chrast R, Smit AB, Verheijen MHG. Oligodendroglial myelination requires astrocyte-derived lipids. PLOS Biology. 2017;15:e1002605. doi: 10.1371/journal.pbio.1002605. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Chen Y, Tian D, Ku L, Osterhout DJ, Feng Y. The selective RNA-binding protein quaking I (QKI) is necessary and sufficient for promoting oligodendroglia differentiation. Journal of Biological Chemistry. 2007;282:23553–23560. doi: 10.1074/jbc.M702045200. [DOI] [PubMed] [Google Scholar]
  10. Chrast R, Saher G, Nave KA, Verheijen MH. Lipid metabolism in myelinating glial cells: lessons from human inherited disorders and mouse models. Journal of Lipid Research. 2011;52:419–434. doi: 10.1194/jlr.R009761. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Darbelli L, Vogel G, Almazan G, Richard S. Quaking regulates neurofascin 155 expression for myelin and axoglial junction maintenance. The Journal of Neuroscience. 2016;36:4106–4120. doi: 10.1523/JNEUROSCI.3529-15.2016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Darbelli L, Richard S. Emerging functions of the quaking RNA-binding proteins and link to human diseases. Wiley Interdisciplinary Reviews: RNA. 2016;7:399–412. doi: 10.1002/wrna.1344. [DOI] [PubMed] [Google Scholar]
  13. Dietschy JM, Turley SD. Thematic review series: brain lipids cholesterol metabolism in the central nervous system during early development and in the mature animal. Journal of Lipid Research. 2004;45:1375–1397. doi: 10.1194/jlr.R400004-JLR200. [DOI] [PubMed] [Google Scholar]
  14. Doerflinger NH, Macklin WB, Popko B. Inducible site-specific recombination in myelinating cells. Genesis. 2003;35:63–72. doi: 10.1002/gene.10154. [DOI] [PubMed] [Google Scholar]
  15. Doukhanine E, Gavino C, Haines JD, Almazan G, Richard S. The QKI-6 RNA binding protein regulates actin-interacting protein-1 mRNA stability during oligodendrocyte differentiation. Molecular Biology of the Cell. 2010;21:3029–3040. doi: 10.1091/mbc.e10-04-0305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Ebersole TA, Chen Q, Justice MJ, Artzt K. The quaking gene product necessary in embryogenesis and myelination combines features of RNA binding and signal transduction proteins. Nature Genetics. 1996;12:260–265. doi: 10.1038/ng0396-260. [DOI] [PubMed] [Google Scholar]
  17. Feng J, Liu T, Qin B, Zhang Y, Liu XS. Identifying ChIP-seq enrichment using MACS. Nature Protocols. 2012;7:1728–1740. doi: 10.1038/nprot.2012.101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Fernø J, Raeder MB, Vik-Mo AO, Skrede S, Glambek M, Tronstad KJ, Breilid H, Løvlie R, Berge RK, Stansberg C, Steen VM. Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action? The Pharmacogenomics Journal. 2005;5:298–304. doi: 10.1038/sj.tpj.6500323. [DOI] [PubMed] [Google Scholar]
  19. Fledrich R, Abdelaal T, Rasch L, Bansal V, Schütza V, Brügger B, Lüchtenborg C, Prukop T, Stenzel J, Rahman RU, Hermes D, Ewers D, Möbius W, Ruhwedel T, Katona I, Weis J, Klein D, Martini R, Brück W, Müller WC, Bonn S, Bechmann I, Nave KA, Stassart RM, Sereda MW. Targeting myelin lipid metabolism as a potential therapeutic strategy in a model of CMT1A neuropathy. Nature Communications. 2018;9:3025. doi: 10.1038/s41467-018-05420-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Guo F, Ma J, McCauley E, Bannerman P, Pleasure D. Early postnatal proteolipid promoter-expressing progenitors produce multilineage cells in vivo. Journal of Neuroscience. 2009;29:7256–7270. doi: 10.1523/JNEUROSCI.5653-08.2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Hardy RJ, Loushin CL, Friedrich VL, Chen Q, Ebersole TA, Lazzarini RA, Artzt K. Neural cell type-specific expression of QKI proteins is altered in quakingviable mutant mice. The Journal of Neuroscience. 1996;16:7941–7949. doi: 10.1523/JNEUROSCI.16-24-07941.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, Cheng JX, Murre C, Singh H, Glass CK. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Molecular Cell. 2010;38:576–589. doi: 10.1016/j.molcel.2010.05.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. Journal of Clinical Investigation. 2002;109:1125–1131. doi: 10.1172/JCI0215593. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Imayoshi I, Sakamoto M, Ohtsuka T, Takao K, Miyakawa T, Yamaguchi M, Mori K, Ikeda T, Itohara S, Kageyama R. Roles of continuous neurogenesis in the structural and functional integrity of the adult forebrain. Nature Neuroscience. 2008;11:1153–1161. doi: 10.1038/nn.2185. [DOI] [PubMed] [Google Scholar]
  25. Kanungo S, Soares N, He M, Steiner RD. Sterol metabolism disorders and neurodevelopment-an update. Developmental Disabilities Research Reviews. 2013;17:197–210. doi: 10.1002/ddrr.1114. [DOI] [PubMed] [Google Scholar]
  26. Kim D, Langmead B, Salzberg SL. HISAT: a fast spliced aligner with low memory requirements. Nature Methods. 2015;12:357–360. doi: 10.1038/nmeth.3317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Kim M, Wende H, Walcher J, Kühnemund J, Cheret C, Kempa S, McShane E, Selbach M, Lewin GR, Birchmeier C. Maf links Neuregulin1 signaling to cholesterol synthesis in myelinating schwann cells. Genes & Development. 2018;32:645–657. doi: 10.1101/gad.310490.117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Krämer A, Green J, Pollard J, Tugendreich S. Causal analysis approaches in ingenuity pathway analysis. Bioinformatics. 2014;30:523–530. doi: 10.1093/bioinformatics/btt703. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Lan F, Bayliss PE, Rinn JL, Whetstine JR, Wang JK, Chen S, Iwase S, Alpatov R, Issaeva I, Canaani E, Roberts TM, Chang HY, Shi Y. A histone H3 lysine 27 demethylase regulates animal posterior development. Nature. 2007;449:689–694. doi: 10.1038/nature06192. [DOI] [PubMed] [Google Scholar]
  30. Langmead B, Salzberg SL. Fast gapped-read alignment with bowtie 2. Nature Methods. 2012;9:357–359. doi: 10.1038/nmeth.1923. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Larocque D, Pilotte J, Chen T, Cloutier F, Massie B, Pedraza L, Couture R, Lasko P, Almazan G, Richard S. Nuclear retention of MBP mRNAs in the quaking viable mice. Neuron. 2002;36:815–829. doi: 10.1016/S0896-6273(02)01055-3. [DOI] [PubMed] [Google Scholar]
  32. Larocque D, Galarneau A, Liu HN, Scott M, Almazan G, Richard S. Protection of p27(Kip1) mRNA by quaking RNA binding proteins promotes oligodendrocyte differentiation. Nature Neuroscience. 2005;8:27–33. doi: 10.1038/nn1359. [DOI] [PubMed] [Google Scholar]
  33. Le Hellard S, Theisen FM, Haberhausen M, Raeder MB, Fernø J, Gebhardt S, Hinney A, Remschmidt H, Krieg JC, Mehler-Wex C, Nöthen MM, Hebebrand J, Steen VM. Association between the insulin-induced gene 2 (INSIG2) and weight gain in a german sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects? Molecular Psychiatry. 2009;14:308–317. doi: 10.1038/sj.mp.4002133. [DOI] [PubMed] [Google Scholar]
  34. Le Hellard S, Mühleisen TW, Djurovic S, Fernø J, Ouriaghi Z, Mattheisen M, Vasilescu C, Raeder MB, Hansen T, Strohmaier J, Georgi A, Brockschmidt FF, Melle I, Nenadic I, Sauer H, Rietschel M, Nöthen MM, Werge T, Andreassen OA, Cichon S, Steen VM. Polymorphisms in SREBF1 and SREBF2, two antipsychotic-activated transcription factors controlling cellular lipogenesis, are associated with schizophrenia in german and scandinavian samples. Molecular Psychiatry. 2010;15:463–472. doi: 10.1038/mp.2008.110. [DOI] [PubMed] [Google Scholar]
  35. Leoni V, Caccia C. Study of cholesterol metabolism in Huntington's disease. Biochemical and Biophysical Research Communications. 2014;446:697–701. doi: 10.1016/j.bbrc.2014.01.188. [DOI] [PubMed] [Google Scholar]
  36. Li Z, Zhang Y, Li D, Feng Y. Destabilization and mislocalization of myelin basic protein mRNAs in quaking dysmyelination lacking the QKI RNA-binding proteins. The Journal of Neuroscience. 2000;20:4944–4953. doi: 10.1523/JNEUROSCI.20-13-04944.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R, 1000 Genome Project Data Processing Subgroup The sequence alignment/Map format and SAMtools. Bioinformatics. 2009;25:2078–2079. doi: 10.1093/bioinformatics/btp352. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biology. 2014;15:550. doi: 10.1186/s13059-014-0550-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Madhavarao CN, Arun P, Moffett JR, Szucs S, Surendran S, Matalon R, Garbern J, Hristova D, Johnson A, Jiang W, Namboodiri MA. Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease. PNAS. 2005;102:5221–5226. doi: 10.1073/pnas.0409184102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Marques S, Zeisel A, Codeluppi S, van Bruggen D, Mendanha Falcão A, Xiao L, Li H, Häring M, Hochgerner H, Romanov RA, Gyllborg D, Muñoz Manchado A, La Manno G, Lönnerberg P, Floriddia EM, Rezayee F, Ernfors P, Arenas E, Hjerling-Leffler J, Harkany T, Richardson WD, Linnarsson S, Castelo-Branco G. Oligodendrocyte heterogeneity in the mouse juvenile and adult central nervous system. Science. 2016;352:1326–1329. doi: 10.1126/science.aaf6463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Mayoral SR, Etxeberria A, Shen YA, Chan JR. Initiation of CNS myelination in the optic nerve is dependent on axon caliber. Cell Reports. 2018;25:544–550. doi: 10.1016/j.celrep.2018.09.052. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Mohamed A, Viveiros A, Williams K, Posse de Chaves E. Aβ inhibits SREBP-2 activation through akt inhibition. Journal of Lipid Research. 2018;59:1–13. doi: 10.1194/jlr.M076703. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Monsma PC, Brown A. FluoroMyelin red is a bright, photostable and non-toxic fluorescent stain for live imaging of myelin. Journal of Neuroscience Methods. 2012;209:344–350. doi: 10.1016/j.jneumeth.2012.06.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Muzumdar MD, Tasic B, Miyamichi K, Li L, Luo L. A global double-fluorescent cre reporter mouse. Genesis. 2007;45:593–605. doi: 10.1002/dvg.20335. [DOI] [PubMed] [Google Scholar]
  45. Myers KR, Liu G, Feng Y, Zheng JQ. Oligodendroglial defects during quakingviable cerebellar development. Developmental Neurobiology. 2016;76:972–982. doi: 10.1002/dneu.22369. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Nwokoro NA, Wassif CA, Porter FD. Genetic disorders of cholesterol biosynthesis in mice and humans. Molecular Genetics and Metabolism. 2001;74:105–119. doi: 10.1006/mgme.2001.3226. [DOI] [PubMed] [Google Scholar]
  47. Ozgen H, Baron W, Hoekstra D, Kahya N. Oligodendroglial membrane dynamics in relation to myelin biogenesis. Cellular and Molecular Life Sciences. 2016;73:3291–3310. doi: 10.1007/s00018-016-2228-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Pertea M, Pertea GM, Antonescu CM, Chang TC, Mendell JT, Salzberg SL. StringTie enables improved reconstruction of a transcriptome from RNA-seq reads. Nature Biotechnology. 2015;33:290–295. doi: 10.1038/nbt.3122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Pertea M, Kim D, Pertea GM, Leek JT, Salzberg SL. Transcript-level expression analysis of RNA-seq experiments with HISAT, StringTie and ballgown. Nature Protocols. 2016;11:1650–1667. doi: 10.1038/nprot.2016.095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Peterson TR, Sengupta SS, Harris TE, Carmack AE, Kang SA, Balderas E, Guertin DA, Madden KL, Carpenter AE, Finck BN, Sabatini DM. mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell. 2011;146:408–420. doi: 10.1016/j.cell.2011.06.034. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Porter FD, Herman GE. Malformation syndromes caused by disorders of cholesterol synthesis. Journal of Lipid Research. 2011;52:6–34. doi: 10.1194/jlr.R009548. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Quan G, Xie C, Dietschy JM, Turley SD. Ontogenesis and regulation of cholesterol metabolism in the central nervous system of the mouse. Developmental Brain Research. 2003;146:87–98. doi: 10.1016/j.devbrainres.2003.09.015. [DOI] [PubMed] [Google Scholar]
  53. Ramírez F, Ryan DP, Grüning B, Bhardwaj V, Kilpert F, Richter AS, Heyne S, Dündar F, Manke T. deepTools2: a next generation web server for deep-sequencing data analysis. Nucleic Acids Research. 2016;44:W160–W165. doi: 10.1093/nar/gkw257. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Rasband MN, Peles E, Trimmer JS, Levinson SR, Lux SE, Shrager P. Dependence of nodal sodium channel clustering on paranodal axoglial contact in the developing CNS. The Journal of Neuroscience. 1999;19:7516–7528. doi: 10.1523/JNEUROSCI.19-17-07516.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Rasband MN, Peles E. Mechanisms of node of ranvier assembly. Nature Reviews. Neuroscience. 2021;22:1–14. doi: 10.1038/s41583-020-00406-8. [DOI] [PubMed] [Google Scholar]
  56. Saher G, Brügger B, Lappe-Siefke C, Möbius W, Tozawa R, Wehr MC, Wieland F, Ishibashi S, Nave KA. High cholesterol level is essential for myelin membrane growth. Nature Neuroscience. 2005;8:468–475. doi: 10.1038/nn1426. [DOI] [PubMed] [Google Scholar]
  57. Saher G, Rudolphi F, Corthals K, Ruhwedel T, Schmidt KF, Löwel S, Dibaj P, Barrette B, Möbius W, Nave KA. Therapy of Pelizaeus-Merzbacher disease in mice by feeding a cholesterol-enriched diet. Nature Medicine. 2012;18:1130–1135. doi: 10.1038/nm.2833. [DOI] [PubMed] [Google Scholar]
  58. Segatto M, Tonini C, Pfrieger FW, Trezza V, Pallottini V. Loss of mevalonate/Cholesterol homeostasis in the brain: a focus on autism spectrum disorder and rett syndrome. International Journal of Molecular Sciences. 2019;20:3317. doi: 10.3390/ijms20133317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Shen L, Shao N, Liu X, Nestler E. Ngs.plot: quick mining and visualization of next-generation sequencing data by integrating genomic databases. BMC Genomics. 2014;15:284. doi: 10.1186/1471-2164-15-284. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Shingu T, Ho AL, Yuan L, Zhou X, Dai C, Zheng S, Wang Q, Zhong Y, Chang Q, Horner JW, Liebelt BD, Yao Y, Hu B, Chen Y, Fuller GN, Verhaak RG, Heimberger AB, Hu J. Qki deficiency maintains stemness of glioma stem cells in suboptimal environment by downregulating endolysosomal degradation. Nature Genetics. 2017;49:75–86. doi: 10.1038/ng.3711. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Sidman RL, Dickie MM, Appel SH. Mutant mice (QUAKING and jimpy) WITH deficient myelination in the central nervous system. Science. 1964;144:309–311. doi: 10.1126/science.144.3616.309. [DOI] [PubMed] [Google Scholar]
  62. Simons M, Krämer EM, Thiele C, Stoffel W, Trotter J. Assembly of myelin by association of proteolipid protein with cholesterol- and galactosylceramide-rich membrane domains. Journal of Cell Biology. 2000;151:143–154. doi: 10.1083/jcb.151.1.143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Singh H, Spritz N, Geyer B. Studies of brain myelin in the "quaking mouse". Journal of Lipid Research. 1971;12:473–481. doi: 10.1016/S0022-2275(20)39497-9. [DOI] [PubMed] [Google Scholar]
  64. Smith ME. The turnover of myelin in the adult rat. Biochimica Et Biophysica Acta (BBA) - Lipids and Lipid Metabolism. 1968;164:285–293. doi: 10.1016/0005-2760(68)90154-9. [DOI] [PubMed] [Google Scholar]
  65. Steen VM, Skrede S, Polushina T, López M, Andreassen OA, Fernø J, Hellard SL. Genetic evidence for a role of the SREBP transcription system and lipid biosynthesis in schizophrenia and antipsychotic treatment. European Neuropsychopharmacology. 2017;27:589–598. doi: 10.1016/j.euroneuro.2016.07.011. [DOI] [PubMed] [Google Scholar]
  66. Tierney E, Conley SK, Goodwin H, Porter FD. Analysis of short-term behavioral effects of dietary cholesterol supplementation in Smith-Lemli-Opitz syndrome. American Journal of Medical Genetics Part A. 2010;152A:91–95. doi: 10.1002/ajmg.a.33148. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Tsunemi T, Ashe TD, Morrison BE, Soriano KR, Au J, Roque RA, Lazarowski ER, Damian VA, Masliah E, La Spada AR. PGC-1α rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function. Science Translational Medicine. 2012;4:142ra97. doi: 10.1126/scitranslmed.3003799. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. van Tilborg E, de Theije CGM, van Hal M, Wagenaar N, de Vries LS, Benders MJ, Rowitch DH, Nijboer CH. Origin and dynamics of oligodendrocytes in the developing brain: implications for perinatal white matter injury. Glia. 2018;66:221–238. doi: 10.1002/glia.23256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R, Jacks T. Restoration of p53 function leads to tumour regression in vivo. Nature. 2007;445:661–665. doi: 10.1038/nature05541. [DOI] [PubMed] [Google Scholar]
  70. Xiang Z, Valenza M, Cui L, Leoni V, Jeong HK, Brilli E, Zhang J, Peng Q, Duan W, Reeves SA, Cattaneo E, Krainc D. Peroxisome-proliferator-activated receptor gamma coactivator 1 α contributes to dysmyelination in experimental models of Huntington's disease. Journal of Neuroscience. 2011;31:9544–9553. doi: 10.1523/JNEUROSCI.1291-11.2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Zerenturk EJ, Sharpe LJ, Ikonen E, Brown AJ. Desmosterol and DHCR24: unexpected new directions for a terminal step in cholesterol synthesis. Progress in Lipid Research. 2013;52:666–680. doi: 10.1016/j.plipres.2013.09.002. [DOI] [PubMed] [Google Scholar]
  72. Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O'Keeffe S, Phatnani HP, Guarnieri P, Caneda C, Ruderisch N, Deng S, Liddelow SA, Zhang C, Daneman R, Maniatis T, Barres BA, Wu JQ. An RNA-sequencing transcriptome and splicing database of Glia, neurons, and vascular cells of the cerebral cortex. Journal of Neuroscience. 2014;34:11929–11947. doi: 10.1523/JNEUROSCI.1860-14.2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Zhao L, Mandler MD, Yi H, Feng Y. Quaking I controls a unique cytoplasmic pathway that regulates alternative splicing of myelin-associated glycoprotein. PNAS. 2010;107:19061–19066. doi: 10.1073/pnas.1007487107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Zhao C, Deng Y, Liu L, Yu K, Zhang L, Wang H, He X, Wang J, Lu C, Wu LN, Weng Q, Mao M, Li J, van Es JH, Xin M, Parry L, Goldman SA, Clevers H, Lu QR. Dual regulatory switch through interactions of Tcf7l2/Tcf4 with stage-specific partners propels oligodendroglial maturation. Nature Communications. 2016;7:10883. doi: 10.1038/ncomms10883. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Zhao C, Dong C, Frah M, Deng Y, Marie C, Zhang F, Xu L, Ma Z, Dong X, Lin Y, Koenig S, Nait-Oumesmar B, Martin DM, Wu LN, Xin M, Zhou W, Parras C, Lu QR. Dual requirement of CHD8 for chromatin landscape establishment and histone methyltransferase recruitment to promote CNS myelination and repair. Developmental Cell. 2018;45:753–768. doi: 10.1016/j.devcel.2018.05.022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Zhou X, He C, Ren J, Dai C, Stevens SR, Wang Q, Zamler D, Shingu T, Yuan L, Chandregowda CR, Wang Y, Ravikumar V, Rao AU, Zhou F, Zheng H, Rasband MN, Chen Y, Lan F, Heimberger AB, Segal BM, Hu J. Mature myelin maintenance requires qki to coactivate PPARβ-RXRα-mediated lipid metabolism. Journal of Clinical Investigation. 2020;130:2220–2236. doi: 10.1172/JCI131800. [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision letter

Editor: Jian Xu1
Reviewed by: Jian Xu2, Richard Q Lu3

In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

Acceptance summary:

Cholesterol is essential for myelin membrane assembly in the central nervous system, yet the mechanisms for temporal control of cholesterol biosynthesis during oligodendrocyte differentiation remain largely unknown. This study describes the role of Qki, commonly known as an RNA-binding protein, in controlling cholesterol biosynthesis in oligodendrocytes by acting as a transcriptional co-activator. These findings establish a previously unrecognized function of Qki in controlling cholesterol metabolism for temporal regulation of myelinogensis in developing central nervous system.

Decision letter after peer review:

Thank you for submitting your article "Qki regulates myelinogenesis through Srebp2-dependent cholesterol biosynthesis" for consideration by eLife. Your article has been reviewed by 3 peer reviewers, including Jian Xu as the Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Marianne Bronner as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Richard Q. Lu (Reviewer #3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

As the editors have judged that your manuscript is of interest, but as described below that additional experiments are required before it is published, we would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). First, because many researchers have temporarily lost access to the labs, we will give authors as much time as they need to submit revised manuscripts. We are also offering, if you choose, to post the manuscript to bioRxiv (if it is not already there) along with this decision letter and a formal designation that the manuscript is "in revision at eLife". Please let us know if you would like to pursue this option. (If your work is more suitable for medRxiv, you will need to post the preprint yourself, as the mechanisms for us to do so are still in development.)

The reviewers found the study of significant interest by reporting a new mechanism linking Qki, cholesterol biosynthesis, myelinogenesis, and Srebp2-mediated transcriptional activation in oligodendrocytes. The experiments were well executed and the data supported the conclusions. Other main strengths of this work are the use of multiple in vivo genetic models and orthogonal approaches for studying cellular and molecular changes upon temporal Qki depletion, thus the technical rigor of this study was very high. Moreover, the studies uncovered a new function for Qki in regulating myelinogenesis by acting as a transcriptional co-activator for Srebp2 in developing brain. These findings provide new insights into the Qki regulation of myelinogenesis. The reviewers also had a number of comments to improve the manuscript, including the analysis of Qki KO on oligodendrocyte and astrocyte development, myelin structure and organization, and additional discussion points below. We have also included the separate review comments from the reviewers.

The reviewers had different views on whether the work represents a significant advance in light of the recent publication from the authors' group reporting a role for Qki in myelin maintenance by functioning as a coactivator of PPARb-RXRa-mediated lipid metabolism (Zhou et al., 2020 JCI 130:2220). Therefore, besides addressing the following comments, it is important to include a section to describe the major differences in the current work and published studies, and the major conceptual advances of the current study. A diagram may be more effective in conveying these messages.

Essential revisions:

1. Regarding the Nestin-cKO studies. Is Qk expressed in astrocytes? The P7 Tm treatment will likely also eliminate Qk in astrocytes. Accordingly, the authors should confirm that astrocyte development is not impacted in this mouse line.

2. A more in-depth analysis of the effect on OPC development is needed. Specifically, a Cre-dependent reporter would be needed to confirm the impact of Qki loss on oligodendrocyte development in the tamoxifen-induced iCKO mice. The proliferation and survival of OPCs and oligodendrocyte in iCKO lines should be included to make sure that the differentiation defects are not due to the progenitor deficits.

3. The introduction touches on tangential topics of psychiatric disorders and white matter, etc.

This manuscript does not endeavor to examine psychiatric disorders, thus introducing this topic is not necessary as its distracting and links between the current studies and this topic are non-existent.

4. Does myelin properly form in these mice? What about Node formation and AIS? The authors have nice EM data, but fail to show whether the myelin organization is affected and whether the axons themselves are impacted. If nodes and AIS forms, then it might be worthwhile to do a time course analysis to decipher when these structures breakdown.

Reviewer #1:

In this manuscript, Hu and colleagues characterized the role of Qki in oligodendrocyte differentiation and myelinogenesis by conditional and inducible inactivation of Qki in neural stem cells (NSCs) or oligodendrocyte precursor cells (OPCs) in neonatal mice during the myelin-forming period of postnatal brain development. The authors found that Qki depletion in NSCs or OPCs impaired cholesterol biosynthesis and myelinogenesis without affecting differentiation into Aspa+Gstpi+ myelinating oligodendrocytes. They next performed RNA-seq-based transcriptomics and ChIP-seq-based chromatin occupancy studies, and identified Qki-5 as a transcriptional co-activator of Srebp2 to control the expression of genes involved in cholesterol biogenesis in oligodendrocytes. Qki depletion impaired Srebp2-mediated transcriptional activation of genes required for cholesterol biosynthesis, thus establishing a new function of Qki as a transcriptional co-activator beyond its known role as an RNA-binding protein.

Overall, this is an important and well-executed study reporting a new and interesting mechanism linking Qki, cholesterol biosynthesis, myelinogenesis, and Srebp2-mediated transcriptional activation in oligodendrocytes. The experiments related to the phenotypic analysis of Qki conditional KO in NSCs and OPCs, and the mechanistic studies of Qki in developing oligodendrocytes were appropriately designed, and the results were carefully analyzed. Another main strengths of this work are the use of multiple in vivo genetic models and orthogonal approaches for studying cellular and molecular changes upon Qki depletion, thus the technical rigor of this study was excellent. Moreover, the detailed functional and mechanistic studies uncovered a new function for Qki in regulating myelinogenesis by acting as a transcriptional co-activator for Srebp2 in developing brain. The manuscript was well written, and the results were carefully interpreted and discussed.

Reviewer #2:

In this paper by Hu and colleagues, the role of the Quaking gene in developmental myelination is explored. Using temporal-lineage specific mouse genetics, they show that loss of Qk results in severe defects in myelination. Mechanistic studies show that cholesterol biosynthesis pathways are dysregulted and that Qk collaboratively regulates subsets of these gens with Srebp2, a known transcriptional regulator of cholesterol associated genes.

Overall, this paper is well executed and the data support the conclusions. The main issue with this manuscript is that the authors just published a very nice paper in JCI showing essentially the same role of Qk in the adult. The only real difference between the published JCI paper and this current manuscript is the timing of the administration of tamoxifen: in the JCI paper it was added at 8w of age, here its added at P7. One could imagine the P7 treatment being included as part of the original analysis conducted for the published JCI paper. The fact that Qk plays an important role in lipid/cholesterol in myelin has already been shown, making the findings contained within this paper incremental and not of interest to a broad audience.

For these reasons, I do not support publication of this manuscript in eLife, as it's more appropriate for specialized journals that target glial biologists and those interested in demyelinating disorders. Below are a few comments meant to improve a well-executed, but incremental paper:

1. Regarding the Nestin-cKO studies. Is Qk expressed in astrocytes? The P7 Tm treatment will likely also eliminate Qk in astrocytes. Accordingly, the authors should confirm that astrocyte development is not impacted in this mouse line.

2. The fact that OPCs appear unaffected further supports the notion that Qk plays a role in myelin biosynthesis via the mechanisms described in their JCI paper (and in this paper). If they want to uncoupled their developmental studies, from their adult studies, a more in-depth analysis of OPC biology and transcriptome might help.

3. The introduction touches on tangential topics of psychiatric disorders and white matter, etc.

This manuscript does not endeavor to examine psychiatric disorders, thus introducing this topic is not necessary as its distracting and links between the current studies and this topic are non-existent.

4. One myelin related question. Does myelin ever properly form in these mice? Have the authors looked at Node formation? What about the AIS? The authors have nice EM data, but fail to show whether the myelin organization is affected and whether the axons themselves are impacted. If nodes and AIS forms, then it might be worthwhile to do a time course analysis to decipher when these structures breakdown.

Reviewer #3:

QKI is essential for CNS myelination and myelin maintenance, however, the underlying mechanisms remain unclear. In this study, Dr. Hu and colleagues defined the of QKI at different stages during oligodendrocyte development. They show that the loss of Qki results in defects in OPC differentiation and myelination but not OPC formation. They further show that Qki5 can interact with a crucial cholesterol biosynthesis regulator Srebp2 and that QKi5 and Srebp2 cooperate to regulate cholesterol biosynthesis genes. The findings that link QKi5 function to Srebp2 and cholesterol biosynthesis is interesting and provide a new insight into the Qki regulation of myelinogenesis. Following concerns need to be addressed to strengthen their conclusions.

1. A cre-dependent reporter would need to confirm the impact of Qki loss on oligodendrocyte development in the tamoxifen-induced iCKO mice.

2. The authors should examine the proliferation and survival of OPCs and oligodendrocyte in iCKO lines to make sure that the differentiation defects are not due to the progenitor deficits.

3. Qk undergoes alternative splicing to express Qki-5, Qki-6, and Qki-7. Qk deletion may also reduce other isoforms besides Qki-5. Could Qki-6 and Qki-7 have a role in OPC differentiation and myelination too?

4. Previous study suggested that nuclear-localized QKI-5 predominantly represses myelination while the cytoplasmic QKI-6 and QKI-7 are essential for promoting OL maturation and myelination (PMID: 20956316). The present study suggests a positive role QKI-5 in cholesterol synthesis and CNS myelination. Could the authors comment on these different observations on the QKI-5 function in OL maturation?

5. Could the authors show a significant reduction of Pol II or Srebp2 target occupancy upon Qki deletion with statistic tests in Figure 7D,E? Could Qki have a role in global gene transcription in addition to cholesterol biosynthesis genes?

6. Is there any evidence that Qki-5 functions as a co-activator of Srebp2 for cholesterol biosynthesis? Since the authors reported Qki-5 interact with PPARb-RXRa for lipid metabolism for myelination, could the authors define how Qki-5 coordinates PPARb-RXRa or Srebp2 for myelination?

eLife. 2021 May 4;10:e60467. doi: 10.7554/eLife.60467.sa2

Author response


The reviewers found the study of significant interest by reporting a new mechanism linking Qki, cholesterol biosynthesis, myelinogenesis, and Srebp2-mediated transcriptional activation in oligodendrocytes. The experiments were well executed and the data supported the conclusions. Other main strengths of this work are the use of multiple in vivo genetic models and orthogonal approaches for studying cellular and molecular changes upon temporal Qki depletion, thus the technical rigor of this study was very high. Moreover, the studies uncovered a new function for Qki in regulating myelinogenesis by acting as a transcriptional co-activator for Srebp2 in developing brain. These findings provide new insights into the Qki regulation of myelinogenesis. The reviewers also had a number of comments to improve the manuscript, including the analysis of Qki KO on oligodendrocyte and astrocyte development, myelin structure and organization, and additional discussion points that are grouped into essential revisions and minor comments below. We have also included the separate review comments from the reviewers.

The reviewers had different views on whether the work represents a significant advance in light of the recent publication from the authors' group reporting a role for Qki in myelin maintenance by functioning as a coactivator of PPARb-RXRa-mediated lipid metabolism (Zhou et al., 2020 JCI 130:2220). Therefore, besides addressing the following comments, it is important to include a section to describe the major differences in the current work and published studies, and the major conceptual advances of the current study. A diagram may be more effective in conveying these messages.

We thank all the editors and reviewers for their enthusiastic and constructive feedback. On the basis of the comments from the editors and reviewers, we have performed 11 experiments and added 20 new figure panels in the revised manuscript. Lastly, we included the following points to clarify the major differences between the current work and the published studies (in particular, Zhou et al., JCI, 2020) and summarize the major conceptual advances of the current study.

1. The focus of the current study is to investigate the transcriptional regulatory mechanism for de novo production of the major myelin lipid –cholesterol– in oligodendrocytes during early developmental stage, whereas the JCI paper (Zhou et al., 2020) focuses on the transcriptional regulation of biosynthesis of the unsaturated fatty acids and very-long-chain fatty acids (which are the main components of phospholipids, sphingolipid, and glycolipids) in oligodendrocytes of adult mice. Although both cholesterol and fatty acids are important lipids in lipid-rich myelin membrane, cholesterol specifically functions as a chaperone in proper sorting of newly synthesized hydrophobic myelin membrane proteins such as PLP during the developmental process (Simons and Trotter, 2007). Besides, cholesterol is a major component of microdomain on the myelin membrane that facilitates the proper localization of myelin proteins and the translation of MBP mRNA (Gielen et al., 2006; Hughes and Appel, 2016; Simons et al., 2000). In the current study, we showed that significant reduction in cholesterol level induced by Qki depletion leads to defect in myelin protein localization observed by patchy MBP staining and impairment of co-localization of myelin proteins such as MBP, PLP, and MAG (Figure 3A, B).

Importantly, the defects in myelin protein assembly in QkNestin-iCKO mice upon Qki loss were not observed in the JCI paper. In summary, compared to phospholipids, sphingolipid, and glycolipids, cholesterol plays a distinct role in facilitating myelin membrane formation; our current study is the first one to demonstrate that Qki regulates cholesterol biosynthesis in oligodendrocytes.

2. Molecular machineries that are involved in transcriptional regulation of cholesterol biosynthesis are different from those in fatty acid metabolism. One of the major differences is the mechanisms through which the major transcription factors are regulated. For example, PGC1α is a critical regulator of PPARβ-RXRα, but it has no direct impact on Srebp2. In addition, Srebp2 is post-translationally processed and translocalized to the nucleus with the help of scaffold proteins such as Scap and Insig, which can sense the availability of cellular cholesterol. In contrast, the main regulatory mechanism of PPARβ-RXRα heterodimer is through ligand binding, which in turn facilitates the interaction with transcription co-factors and activates transcription of fatty acid metabolic genes. The biosynthesis of cholesterol and fatty acids have to be coordinated, yet few co-factors have been identified to be shared by Srebp2 and PPARβ-RXRα. Our JCI paper and the current study discovered that Qki is actually a cofactor for both Srebp2 and PPARβ-RXRα, thereby functions as a major regulator that coordinates the biosynthesis of cholesterol and fatty acids in myelination.

3. Although both cholesterol ((Saher et al., 2005) and the current study) and fatty acids (Dimas et al., 2019) are essential for de novo myelination, the stability of these types of lipids are quite different. In the JCI paper, we discovered that fatty acids in mature myelin undergo fast turnover, and Qki-5/PPARβ/RXRα is the major regulator for fatty acid metabolism in mature myelin. However, in the JCI paper, we didn’t identify cholesterol metabolism as a pathway that is regulated by Qki in the adult mice, and the reason is that unlike fatty acids, cholesterol is actually quite stable in mature myelin with a half-life of more than 5 years in human and more than 1 year in mouse (Ando et al., 2003; Russell et al., 2009; Smith, 1968), so the cholesterol metabolic genes are generally suppressed in adult oligodendrocytes because the constant biosynthesis of cholesterol is not needed due to its slow turnover rate. Therefore, developmental stage is the only period in which cholesterol metabolism can be effectively studied in oligodendrocytes, and this is why only the current study but not the JCI paper could discover Qki as a major regulator of cholesterol biosynthesis.

4. It has been known that reduced cholesterol level in qkv mice is secondary to impairment of oligodendrocyte differentiation and maturation during development (Baumann et al., 1968; Singh et al., 1971). However, in the current study, we uncovered a previously uncharacterized function of Qki in controlling transcription of the genes involved in cholesterol biosynthesis without affecting the differentiation of Aspa+Gstpi+ myelinating oligodendrocytes, and we propose that cholesterol metabolism controlled by Qki-5 is a determinant for proper function of myelinating oligodendrocytes, and ultimately for temporal control of CNS myelinogenesis.

Essential revisions:

1. Regarding the Nestin-cKO studies. Is Qk expressed in astrocytes? The P7 Tm treatment will likely also eliminate Qk in astrocytes. Accordingly, the authors should confirm that astrocyte development is not impacted in this mouse line.

Qki is moderately expressed in both nucleus and cytosol in GFAP+ astrocytes of P21 mice, while GFAP- cells (predicted to be oligodendrocyte lineage cells) show stronger Qki expression (>2 fold higher than that in GFAP+ astrocytes) with predominant localization in the nucleus (Author response image 1).

Author response image 1. Qki is moderately expressed in GFAP+ astrocytes.

Author response image 1.

Representative images and quantification of immunofluorescent staining of Qki and GFAP in the cortex/corpus callosum/hippocampus tissues in WT mice at P21. Arrow: Qki+GFAP+ cells. Arrow head: Qki+GFAP- cells. CTX: cortex. CC: corpus callosum. HC: hippocampus. Scale bars, 100 μm.

We provide the following evidence to show that astrocyte development is not impacted by Qki depletion. First, a Cre-dependent mTmG reporter was used for in-depth analysis of the effect of Qki depletion on astrocyte development. In the P21 NestinCreERT2;mTmG mice, the percentage of GFP+GFAP+ cells among the total GFAP+ astrocytes is 9.48% (Author response image 2A, B); In the P21 Qk-Nestin-iCKO;mTmG mice, the percentage of GFP+GFAP+ cells (indicating Qki-depleted astrocytes) among the total GFAP+ astrocytes is 11.59%, which is similar as that in control (Author response image 2A, B), indicating that depletion of Qki in Qk-Nestin-iCKO mice does not affect the astrocyte development. Second, Sox9 has been shown to be a specific and potent marker for astrocyte by Dr. Ben Deneen and others (Laug et al., 2019). So, to reinforce our finding, we further co-labeled GFAP+ astrocytes with Sox9 (Sun et al., 2017).

Author response image 2. GFP is expressed in a small subpopulation of GFAP+ astrocytes, and Qki loss does not alter GFAP expression.

Author response image 2.

(A) Representative images of immunofluorescent staining of GFP and GFAP in the corpus callosum tissues in Qk- Nestin-iCKO and control mice two weeks after tamoxifen injection. Arrowhead: GFAP+GFP-cells. Arrow: GFAP+GFP+ cells. Scale bars, 100 μm. (B) Quantification of GFAP+GFP+ cells in Qk-Nestin-iCKO (n = 4) and control (n = 4) mice two weeks after tamoxifen injection shown in A. (C) Quantification of relative GFAP expression in GFAP+GFP+ cells from Qk-Nestin-iCKO (n = 4) and control (n = 4) mice two weeks after tamoxifen injection shown in A.

Similarly, Sox9+GFAP+GFP+ cells only constituted a small population of total Sox9+GFAP+ astrocytes in both Qk-Nestin-iCKO;mTmG mice (15.92%) and control Nestin-CreERT2;mTmG mice (16.22%) (New Figure 2—figure supplement 2B). Collectively, these data suggested that majority of GFAP+ astrocytes are developed prior to P7 and therefore are not targeted by Nestin-CreERT2 inducible system with P7 tamoxifen treatment. Previous studies have shown that astrocyte precursor cells are derived from neural stem cells around E16-E18 (Ge et al., 2012), and astrocyte precursors and astrocytes are actively expanding in number and significantly decrease Nestin expression during the first postnatal week (Cahoy et al., 2008; Clavreul et al., 2019), supporting our observation that the impact of Qki depletion under the control of Nestin-CreERT2 promoter at P7 on astrocyte population is quite limited. We have included this result in text line “241-248” in the revised manuscript.

In addition, the recruitment of GFP+GFAP+ cells to the dysmyelinating regions and enhancement of GFAP expression in these cells were not affected upon Qki depletion (Author response image 2C), further suggesting that Qki loss does not alter the astrocyte activity.

Taken together, our data indicated that: (1) P7 tamoxifen injection in the NestinCreERT2mice only leads to expression of Cre activity in around 10% of astrocytes which are newly differentiated from neural stem cells after P7; (2) depletion of Qki in these astrocytes does not lead to impairment of their development at P21; and (3) depletion of Qki in these astrocytes does not lead to impairment of their activity at P21. Lastly, the dysmyelinating phenotypes observed in the Qk-Nestin-iCKO mice were further validated in the Qk-Plp-iCKO mice.

2. A more in-depth analysis of the effect on OPC development is needed. Specifically, a Cre-dependent reporter would be needed to confirm the impact of Qki loss on oligodendrocyte development in the tamoxifen-induced iCKO mice.

In our original manuscript, we found that the number of Pdgfrα+ OPCs in the developing cortex tissues in Qk-Nestin-iCKO mice was slightly higher than that in control mice (Figure 2A), probably due to a compensatory increase in the proliferation of OPCs in response to hypomyelination. In consistence with our finding, a previous study also showed that the number of Pdgfrα+ OPCs in QKIFL/FL;Olig2–Cre mice was slightly higher than that in control mice (Darbelli et al., 2016). Notably, 92.6% of Pdgfrα+ OPCs in QkNestin-iCKO mice lacked expression of Qki, indicating that Qki does not affect the generation or survival of OPCs (Figure 2A).

The activity of the Plp1 promoter in the CNS of early neonatal mice is restricted to a subset of OPCs poised to differentiate into myelinating oligodendrocytes (Guo et al., 2010). To further determine the effect of Qki on OPC development, we crossed the mice bearing the mTmG reporter line (Muzumdar et al., 2007) with Qk-Plp-iCKO mice or control mice. The mTmG reporter, in which expression of cell membrane-localized tdTomato (mT) is replaced by cell membrane-localized EGFP (mG) in Cre recombinase-expressing cells, enabled us to trace newly formed oligodendroglial lineage cells (after tamoxifen injection) including a subset of OPCs according to the GFP signals. On the basis of this Cre-dependent reporter, we confirmed that Plp1-CreERT2; mTmG cohort labels OPC population as indicated by the Pdgfrα+GFP+ double positive cells (New Figure 4—figure supplement 1F). More importantly, Qki loss did not alter the number of Pdgfrα+GFP+ cells (New Figure 4—figure supplement 1F), suggesting that the development and survival of OPC population was not altered upon Qki depletion. We have included this result in text line “316-319” in the revised manuscript.

The proliferation and survival of OPCs and oligodendrocyte in iCKO lines should be included to make sure that the differentiation defects are not due to the progenitor deficits.

No alteration in proliferation was observed upon Qki depletion in OPC population (Pdgfrα+ cells) or oligodendroglial lineage cells (Olig2+ cells) co-labeled by proliferating marker, Ki67 (New Figure 4—figure supplement 2A, B) between Qk-PlpiCKO and control. In addition, comparable numbers of TUNEL positive cells (which are very few) were found between Qk-Nestin-iCKO and control (New Figure 2—figure supplement 1C). These data suggest that depletion of Qki does not affect the proliferation and survival of OPC, and the defect in differentiation of Olig2+Aspa-Gstpi- oligodendroglial lineage cells was not due to impaired OPC development. We have included this result in text line “320-325” in the revised manuscript.

3. The introduction touches on tangential topics of psychiatric disorders and white matter, etc.

This manuscript does not endeavor to examine psychiatric disorders, thus introducing this topic is not necessary as its distracting and links between the current studies and this topic are non-existent.

We have removed this part in the Introduction section as the reviewer suggested.

4. Does myelin properly form in these mice?

To decipher whether myelin was properly formed in Qk-Nestin-iCKO mice, a time course analysis of MBP expression was performed in the corpus callosum. As shown in New Figure 1—figure supplement 1C, Qki depletion slowed down the myelin formation during brain development observed from P12 (5 days after tamoxifen injection) to P21 (14 days after tamoxifen injection), during which myelin is initiated and actively generated, ultimately resulting in failure of proper myelination formation and motor deficit at P21 (Figure 1C, Video 1). We have included this result in text line “161-166” in the revised manuscript. In addition to the corpus callosum tissues, hypomyelination was observed in optic nerves of Qk-Nestin-iCKO mice (Figure 1G) at P21, suggesting that Qki depletion leads to global abnormalities in the CNS myelin formation.

What about Node formation and AIS? The authors have nice EM data, but fail to show whether the myelin organization is affected and whether the axons themselves are impacted.

To ask if the formation of node of Ranvier is affected by Qki depletion, we focused on examining the node formation in the optic nerve, where rapid and robust myelination occurs during development. By labeling the nodes using antibodies against paranodal protein (Caspr) and nodal proteins (AnkG or PanNav), we found that Qki depletion leads to defect in intact node formation at P21 (14 days after P7 tamoxifen injection) (New Figure 1—figure supplement 1D). Consistently, paranodal defects were also observed in QKIFL/FL;Olig2–Cre mice in a previous study (Darbelli et al., J. Neurosci, 2016). We have included this result in text line “166-169” in the revised manuscript.

In addition to the node formation, we further asked if Qki loss impacts on the axon initial segment (AIS) structure. We found that the length of AIS labeled by AnkG at the proximal axon adjacent to cell body (NeuN) was not altered in the cortex region of Nestin-Qki-iCKO mice compared to control mice as shown in New Figure 1—figure supplement 1K-M, suggesting that generation of action potential was not affected upon Qki depletion. We have included this result in text line “187-191” in the revised manuscript.

Although myelin formation was severely affected, we did not observe the alteration of thickness and number of axons (New Figure 1—figure supplement 1I, J). In addition, no axonal damage was found, as shown in Figure 1I.

If nodes and AIS forms, then it might be worthwhile to do a time course analysis to decipher when these structures breakdown.

As node formation was severely affected by Qki depletion at P21, we further examined when this occurred during early myelin development through a time course analysis. Previous studies showed that clustering of ion channels at the nodes requires proper myelination (Rasband and Peles, 2020; Rasband et al., 1999). As myelination is rapidly formed at its peak from P14 in the optic nerve (Mayoral et al., 2018), we monitored earlier times (P14 and P17) to ask if myelin defect induced by Qki depletion affects de novo formation of nodes. Defect in node formation was observed as early as P14, which cannot be overcome at P21 (New Figure 1—figure supplement 1E, F), and this observation is in line with the defect in myelination (New Figure 1—figure supplement 1C). Specifically, total number of nodes (including both intact and the incomplete nodes) in the optic nerve was decreased upon Qki depletion (New Figure 1figure supplement 1G). Importantly, the percentage of intact nodes among the total nodes was also significantly reduced with Qki depletion (New Figure 1—figure supplement 1H). Notably, Qki depletion at P14 showed streaks of Caspr+ signals instead of clustering/localization of Caspr, a component of the axoglial junctions indicating the proper paranode formation (New Figure 1—figure supplement 1E, F). As it was previously reported that paranode formation precedes node clustering in the CNS (Rasband et al., 1999; Zhang et al., 2020), our observation suggests that failure of paranode formation due to defect in myelination upon Qki depletion ultimately leads to failure of node formation during the critical time of myelin development. We have included this result in text line “169-182” in the revised manuscript.

It has been shown that Qki depletion in oligodendrocyte lineage exhibits ultrastructural paranodal defects caused by reduced expression of neurofascin 155, an axoglial junctional protein (Darbelli et al., 2016). Additionally, myelin-specific lipid called galactolipids (GalC) has been studies to be essential for proper CNS node formation (Dupree et al., 1998), implying the importance of myelin lipid in node formation. Our study further sheds light on the understanding of the importance of myelin lipid metabolism (particularly cholesterol) regulated by Qki for proper myelination and formation of node of Ranvier.

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Data Citations

    1. Zhou X, Shin S, He C, Zhang Q, Ren J, Dai C, Shingu T, Yuan L, Wang Y, Chen Y, Lan F, Hu J. 2021. RNA-seq-1. NCBI Gene Expression Omnibus. GSE145116
    2. Zhou X, Shin S, He C, Zhang Q, Ren J, Dai C, Shingu T, Yuan L, Wang Y, Chen Y, Lan F, Hu J. 2021. RNA-seq-2. NCBI Gene Expression Omnibus. GSE145117
    3. Zhou X, Shin S, He C, Zhang Q, Ren J, Dai C, Shingu T, Yuan L, Wang Y, Chen Y, Lan F, Hu J. 2021. Genome-wide maps of Qki-5, Srebp2, and Pol II in oligodendrocyte. NCBI Gene Expression Omnibus. GSE144756
    4. Zhou X, He C, Ren J, Dai C, Stevens SR, Wang Q, Zamler D, Shingu T, Yuan L, Chandregowda CR, Wang Y, Ravikumar V, Rao A, Zhou F, Zheng H, Rasband MN, Chen Y, Lan F, Heimberger AB, Segal BM, Hu J. 2020. Genome-wide maps of Qki-5 and PPARb in mouse oligodendrocytes. NCBI Gene Expression Omnibus. GSE126577

    Supplementary Materials

    Figure 1—source data 1. Exact p-values for statistical analysis.
    Figure 2—source data 1. Exact p-values for statistical analysis.
    Figure 3—source data 1. Exact p-values for statistical analysis.
    Figure 4—source data 1. Exact p-values for statistical analysis.
    Figure 5—source data 1. Exact p-values for statistical analysis.
    Figure 6—source data 1. Exact p-values for statistical analysis.
    Figure 7—source data 1. Exact p-values for statistical analysis.
    Supplementary file 1. A complete list of the sequences of the primer pairs used in this study.
    elife-60467-supp1.docx (44.1KB, docx)
    Transparent reporting form

    Data Availability Statement

    Sequencing data have been deposited in GEO under accession codes GSE145116, GSE145117 and GSE144756.

    The following datasets were generated:

    Zhou X, Shin S, He C, Zhang Q, Ren J, Dai C, Shingu T, Yuan L, Wang Y, Chen Y, Lan F, Hu J. 2021. RNA-seq-1. NCBI Gene Expression Omnibus. GSE145116

    Zhou X, Shin S, He C, Zhang Q, Ren J, Dai C, Shingu T, Yuan L, Wang Y, Chen Y, Lan F, Hu J. 2021. RNA-seq-2. NCBI Gene Expression Omnibus. GSE145117

    Zhou X, Shin S, He C, Zhang Q, Ren J, Dai C, Shingu T, Yuan L, Wang Y, Chen Y, Lan F, Hu J. 2021. Genome-wide maps of Qki-5, Srebp2, and Pol II in oligodendrocyte. NCBI Gene Expression Omnibus. GSE144756

    The following previously published dataset was used:

    Zhou X, He C, Ren J, Dai C, Stevens SR, Wang Q, Zamler D, Shingu T, Yuan L, Chandregowda CR, Wang Y, Ravikumar V, Rao A, Zhou F, Zheng H, Rasband MN, Chen Y, Lan F, Heimberger AB, Segal BM, Hu J. 2020. Genome-wide maps of Qki-5 and PPARb in mouse oligodendrocytes. NCBI Gene Expression Omnibus. GSE126577


    Articles from eLife are provided here courtesy of eLife Sciences Publications, Ltd

    RESOURCES